Salivary gland regeneration
Muscarinic agonists encapsulated in hydrogels target acinar progenitor cells to regenerate salivary glands, addressing the lack of regenerative treatments for xerostomia, offering long-term saliva restoration.
Patent Information
- Application Number
- JP2021555150
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-12-10
- Filing Date
- 2019-12-10
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2039-12-10
AI Technical Summary
There are no effective regenerative treatments for salivary gland dysfunction, such as xerostomia, caused by conditions like Sjögren's syndrome or radiation therapy, which severely impair saliva production and quality of life, with current treatments providing only temporary relief and undesirable side effects.
Compositions and methods involving muscarinic agonists encapsulated in hydrogels, specifically targeting acinar progenitor cells in the salivary glands, promote acinar cell regeneration and restore functional salivary acini by mimicking parasympathetic signaling.
The approach regenerates functional salivary glands, providing long-term relief from xerostomia by enhancing acinar cell proliferation and saliva production, applicable to both human and animal subjects.
Smart Images

Figure 0007595883000002 
Figure 0007595883000003 
Figure 0007595883000004
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119(e) of Provisional Application No. 62 / 777,459, filed December 10, 2018, which is incorporated by reference in its entirety.
[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with Government support under Grant No. U24DE026914 awarded by the National Institutes of Health. The United States Government has certain rights in the invention. [Background technology]
[0003] Dysfunction of the salivary glands (SG) seriously impairs the oral health and quality of life of patients: saliva protects the oral mucosa, facilitates food digestion and articulation, and aids in the remineralization of dental hard tissues. Dry mouth, or xerostomia, can arise from irreversible pathological injury resulting from the autoimmune disease Sjögren's syndrome (1-2 million people in the US), or from therapeutic radiation for head and neck cancer, where the SG is inadvertently irradiated along with the tumor (60,000 people / year in the US). Loss of the regenerative capacity of this tissue precludes the production of saliva and severely impairs the quality of life of these patients. There are no available regenerative therapeutics for salivary dysfunction, and new, transformative solutions are needed.
[0004] Currently, the standard of care is to recommend palliative treatments such as saliva substitutes or artificial saliva, and / or systemic sialagogues. Cevimeline and pilocarpine are two FDA-approved muscarinic agonists that promote the transient secretion of saliva. Pilocarpine is a nonselective muscarinic agonist, while cevimeline has a higher affinity for the M1 and M3 muscarinic receptor subtypes, both of which are expressed in the submandibular and sublingual glands. Although these drugs are effective in promoting short-term saliva production when taken three to four times daily, they are associated with undesirable parasympathetomimetic side effects, including excessive sweating and diarrhea, headache, and blurred vision, which reduce patient compliance. Recently, it was reported that long-term oral use of cevimeline or pilocarpine in patients improves salivary gland function (Barbe (2017) J. Evid. Based Dent. Pract. 17(3):268-270). Continuous oral administration of pilocarpine to mice treated with gamma irradiation to the head and neck promoted salivary flow compared to untreated controls (Taniguchi et al. (2019) Acta Histochem Cytochem. 52(3):45-58), suggesting that muscarinic agonism may promote salivary gland repair, although how this was achieved remains to be determined. There remains a need for better ways to treat salivary dysfunction, particularly regenerative therapies that can restore salivary acinar cells and saliva production. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Barbe(2017)J.Evid.Based Dent.Pract.17(3):268-270 [Non-Patent Document 2] Taniguchi et al.(2019)Acta Histochem Cytochem.52(3):45-58 Summary of the Invention [Means for solving the problem]
[0006] Compositions and methods are provided for salivary gland regeneration by promoting acinar cell replacement. + It was found that acinar progenitor cells, including progenitor cells, are essential for the replenishment of acinar cells with the unexpected ability to repopulate the tissue after radiation-induced damage. It was also found that cholinergic nerves play a pivotal role in controlling acinar cell replacement during homeostasis, and this neuronal influence can be reproduced by adding cholinergic mimetics to acinar progenitor cells. Thus, by directly targeting acinar progenitor cells in tissues with cholinergic and / or muscarinic agonists, it is possible to regenerate the secretory portion of the salivary gland and provide restoration of functional salivary acini and treat oral disorders such as xerostomia associated with radiation therapy or Sjögren's syndrome.
[0007] In one aspect, a composition is provided that includes a muscarinic agonist encapsulated in a hydrogel formulated for local administration to the salivary glands for use in treating xerostomia. Such compositions can be used to treat xerostomia, such as that caused by damage to the salivary glands due to radiation or autoimmune diseases (e.g., Sjogren's syndrome).
[0008] In certain embodiments, the muscarinic agonist is selective for the M1 and / or M3 muscarinic receptor subtypes. In one embodiment, the muscarinic agonist is cevimeline.
[0009] In certain embodiments, the muscarinic agonist is pilocarpine.
[0010] In certain embodiments, the hydrogel comprises an alginate. The alginate may be ionically crosslinked with a divalent cation. In some embodiments, the alginate is ionically crosslinked with a divalent calcium cation (Ca2+ ) is ionically cross-linked.
[0011] In certain embodiments, the concentration of alginate in the hydrogel ranges from about 2 to about 10 weight percent (wt%), including any wt% within this range, such as 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 wt%.
[0012] In certain embodiments, the alginate is at least partially oxidized. In some embodiments, about 2% to about 10% of the alginate is oxidized, including any percentage within this range, such as 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%. In one embodiment, the alginate in the hydrogel is about 2% oxidized and is at a concentration of 5% by weight.
[0013] In certain embodiments, the hydrogel maintains delivery of the muscarinic agonist for at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks or more after administration to a subject, hi some embodiments, the hydrogel maintains delivery of the muscarinic agonist for up to 30 days.
[0014] In certain embodiments, the composition further comprises a contrast agent, for example, to allow confirmation of localization of the composition to the salivary gland by medical imaging after administration. In some embodiments, the contrast agent is a microbubble (e.g., for use in ultrasound) or a radiopaque contrast agent (e.g., for use in X-ray imaging).
[0015] In certain embodiments, the composition further comprises a pharma- ceutically acceptable excipient.
[0016] In another aspect, a kit is provided that includes a composition comprising a muscarinic agonist encapsulated in a hydrogel and instructions for treating xerostomia, as described herein. In some embodiments, the kit further includes a means for delivering the composition to a subject. For example, the kit may include a first syringe containing a composition comprising a muscarinic agonist encapsulated in an alginate hydrogel, a second syringe containing a solution comprising calcium chloride, and a luer lock, and the second syringe can be connected to the first syringe via the luer lock. The first syringe containing a composition comprising a muscarinic agonist encapsulated in an alginate hydrogel can be stored frozen. In some embodiments, the muscarinic agonist in the kit is cevimeline or pilocarpine.
[0017] In another aspect, a method of treating a subject with xerostomia is provided, the method comprising locally administering to a salivary gland of the subject a therapeutically effective amount of a composition comprising a muscarinic agonist encapsulated in a hydrogel.
[0018] In certain embodiments, the composition is injected into or adjacent to a salivary gland.
[0019] In certain embodiments, multiple therapeutically effective doses of the composition are administered to the subject.
[0020] In certain embodiments, the xerostomia is caused by damage to the salivary glands from radiation or Sjogren's syndrome.
[0021] In certain embodiments, the method further includes performing medical imaging (e.g., ultrasound) or palpation to identify the location of the salivary glands prior to injection.
[0022] In certain embodiments, a method of promoting salivary gland regeneration in a subject in need thereof, the method comprising locally administering at least one of a cholinergic agonist or a muscarinic agonist to acinar progenitor cells and acinar cells of the salivary gland to promote proliferation of the acinar progenitor cells and acinar cells, thereby increasing saliva production.
[0023] In certain embodiments, the cholinergic agonist comprises at least one of acetylcholine or an acetylcholine analog. In some embodiments, the acetylcholine analog is carbachol.
[0024] In certain embodiments, the acinar progenitor cells are SOX2 + In some embodiments, the SOX2 + Acinar progenitor cells are AQP57Ki67 + In another embodiment, the SOX27AQP57Ki67 + SOX2 containing acinar progenitor cells + The acinar progenitor cells are mucin (MUC)19- cells.
[0025] In some embodiments, the method further comprises the step of isolating SOX2 from the salivary glands of a subject to be treated. + Isolating acinar progenitor cells and isolating SOX2 + The method further includes expanding the acinar progenitor cells and then transplanting the expanded cells into a salivary gland of the subject.
[0026] In some embodiments, prior to implantation, the expanded cells are provided with an engineered tissue construct or biocompatible matrix that provides a controlled release of at least one cholinergic or muscarinic agonist to the expanded cells. The controlled release may include at least one of delayed release, sustained release, gradient release, time release, patterned release, or spatial release. The engineered tissue construct or biocompatible matrix may include a biodegradable natural polymer or macromer, such as a biocompatible hydrogel.
[0027] In some embodiments, the subject treated by the methods described herein has an oral disorder, such as a disorder that affects the production of saliva. Examples of oral disorders include, but are not limited to, salivary gland tumors, cystic fibrosis, Sjogren's syndrome, sialadenitis, parotitis, sialoangitis, sialodochitis, sialolithiasis, sialodocholithiasis, mucocele, ranula, hyposecretion, hypersalivation, sialorrhea, xerostomia, benign lymphoepithelial lesions of salivary glands, sialectasia, sialosis, stenosis of salivary duct, and stricture of salivary duct. In other embodiments, the subject may have previously been treated with radiation effective to cause xerostomia. The methods described herein can be used to treat human subjects for such oral disorders that affect saliva production (i.e., xerostomia). It will be appreciated that the methods described herein also find use in veterinary applications for the treatment of xerostomia in farm animals, including, but not limited to, pets such as dogs and cats, and livestock such as sheep, goats, pigs, horses, and cows.
[0028] Other embodiments described herein relate to a method of promoting salivary gland regeneration in a subject in need thereof by isolating and expanding SOX2+ acinar progenitor cells of the salivary gland of the subject, and then transplanting the expanded cells into the salivary gland of the subject. + Acinar progenitor cells are AQP57Ki677MUC19 - It may be a cell.
[0029] In some embodiments, prior to and / or after transplantation of the expanded cells, the expanded cells may be administered at least one of a cholinergic or muscarinic agonist to promote the generation of acinar cells.
[0030] In other embodiments, the expanded cells can be provided in an engineered tissue construct or a biocompatible matrix. The engineered tissue construct or biocompatible matrix can provide a controlled release of at least one cholinergic or muscarinic agonist to the expanded cells, the controlled release comprising at least one of delayed release, sustained release, gradient release, time release, patterned release, or spatial release. [Brief description of the drawings]
[0031] [Figure 1A]We show that SOX2 marks progenitor cells that give rise to acinar cells, but not ductal cells, in adult salivary glands. [Figure 1A] Representative images of adult human submandibular (SMG), sublingual (SLG), and parotid (PG) salivary glands (non-IR, 28–33 years old) immunostained for SOX2, epithelium (E-cadherin, ECAD) or CD44, and nuclei. Unidirectional arrows indicate SOX2-expressing acinar cells. Scale bar is 20 μm. [Figure 1B] Wild-type mouse SMG and SLG stained for SOX2, ECAD, and nuclei. Arrowheads indicate SOX2-expressing cells. Scale bar is 50 μm. Yellow dashed line indicates the border between SMG and SLG. [Figure 1C] Sox2eGFP sublingual salivary glands (SLG) immunostained for GFP and the differentiated acinar marker mucin 19 (MUC19). White dashed lines outline Sox2eGFP+MUC19(-) cells. Scale bar = 20 μm. [Fig. 1D] AQP5+SOX2+ cells as a percentage of total AQP5+ acinar cells. [Fig. 1E] SLG immunostained for SOX2, Ki67, and epithelial marker E-cadherin (ECAD). White arrows indicate proliferating Ki67+SOX2+ cells. White lines outline individual cells and nuclei. Scale bar = 10 μm. [Fig. 1F] Representative images of Sox2 lineage-traced SLG. Recombination was induced in Sox2CreERT2, Rosa26mTmG mice, and salivary glands were traced for 24 h and 30 days before immunostaining for SOX2, acinar markers AQP5 and MUC19, and ductal marker KRT8. * indicates MUC19(-)Sox2CreERT2GFP(+) cells. Scale bar = 30 μm. mT = membrane-bound Tomato. Data information: Cells quantified in (Figure 1D) were counted from n = 5, three non-consecutive sections of female adult SLG. Data are presented as mean ± SD. [Figure 1B] Same as above. [Figure 1C] Same as above. [Figure 1D] Same as above. [Figure 1E] Same as above. [Figure 1F] Same as above. [Figure 2A] SOX2 and SOX2+ cells are essential for salivary acinar cell replenishment. [Fig. 2A], [Fig. 2B] Sox2 or SOX2+ cells were ablated in the SLG of Sox2CreERT2;Sox2fl / fl;Rosa26mTmG / + mice (Fig. 2A, see schematic) or Sox2CreERT2Rosa26DTA;Rosa26mTmG / + mice (Fig. 2B, see schematic). Sections were immunostained for AQP5, KRT8, or ECAD and nuclei. Scale bar = 50 μm. Dashed white lines indicate the outline of ducts. n = 3 per genotype. [Figure 2C], [Figure 2D] Quantification of ductal area in Sox2CreERT2;Sox2fl / fl (Figure 2C) or Sox2CreERT2Rosa26DTA;Rosa26mTmG / + SLGs (Figure 2D) expressed as a percentage of the total epithelial area. (Figure 2C), in the right graph, the number of SOX2+ cells in Sox2CreERT2;Sox2fl / fl SLGs was expressed as a percentage of the total cells. (Figure 2D), in the right graph, the total number of KRT8+ ductal, AQP5+ and SOX2+ acinar cells in wild-type and Sox2CreERT2Rosa26DTA;Rosa26mTmG / + mice was counted. Data information: Calculation of cell number / ductal area was performed on three non-consecutive fluorescent sections of each SLG from n=3 mice / genotype. Data (n=3) in (Figures 2C and 2D) are means ± SD and analyzed by Student's t-test: in (Figure 2C), *P=0.011 and **P=0.0041, and in (Figure 2D), left graph, **P=0.0015 and right graph, ***P=0.0007 and **P=0.0018. [Figure 2B] Same as above. [Figure 2C] Same as above. [Figure 2D] Same as above. [Figure 3A]We show that parasympathetic nerves are necessary to maintain SOX2+ cells and promote acinar cell replacement via SOX2. [Figure 3A] Schematic diagram shows the time course and location of denervation of the chorda tympani (CT) in adult mice. [Figure 3B] Gene expression (qPCR) analysis of intact (uninjured contralateral gland) and nerve-transected SLGs 7 and 30 days (D7 or D30) after surgery. Gene expression was normalized to Rsp18 and intact controls for each time point. [Figure 3C-3F] Control and nerve-transected SLGs were immunostained 7 days after denervation for nerve (GFRa2), acinar cells (AQP5 and MIST1), duct cells (KRT8), and epithelial cells (ECAD). The numbers of SOX2+, AQP5+, MIST1+, KRT8+, and KRT5+ cells in control and transected SLGs were counted and expressed as a percentage of the number of cells in control SLGs (Figure 3F). Scale bars in (Figures 3C, 3D and 3E) = 25 μm. [Figure 3G], [Figure 3H] Recombination was induced in Sox2CreERT2;Rosa26mTmG mice 3 days after nerve transection and SLGs were followed for 11 days before being immunostained for TUBB3. The percentage of GFP+ and mT+ acinar cells in control and transected glands is shown in (Figure 3G). Scale bars in (Figure 3H) = 25 μm. Data information: Data (n=5) in (Figure 3B) are means ± SEM and were analyzed using one-way ANOVA with post-hoc Dunnett's test. Sox2(D7)*P=0.0455, Tubb3(D7)**P=0.0082, Tubb3(D30)**P=0.0091, Vip(D7)**P=0.0098, Vip(D30)**P=0.0063, Vacht(D7)**P=0.0071, Muc19(D7)*P=0.0419, Aqp5(D7)*P=0.0468. Data in (Figures 3F and 3G) were calculated from three non-consecutive fluorescent sections of each SLG from n=5 mice / group or genotype, are means ± SD, and analyzed by Student's t-test. SOX2+ *P=0.0197, AQP5+ *P=0.0106, %GFP+ ***P=0.0000096, %mT+ ***P=0.0000096. [Figure 3B] Same as above. [Figure 3C] Same as above. [Figure 3D] Same as above. [Figure 3E] Same as above. [Figure 3F] Same as above. [Figure 3G] Same as above. [Figure 3H] Same as above. [Figure 4A] We show that muscarinic signaling promotes SOX2+ cell proliferation. [Figure 4A] Adult SLGs were immunostained for SOX2, CHRM3, and nuclei. Images are 6 μm (left) and 1 μm (right) projections of 1-μm and 0.175-μm confocal sections. Scale bar = 10 μm. [Figure 4B] The percentage of epithelial SOX2+ cells that were CHRM1+ or CHRM3+ was counted using flow cytometry and expressed as a percentage of total EpCAM+SOX2+ cells. [Figure 4C], [Figure 4D] Adult SLGs from mice treated with pilocarpine or saline (control) were immunostained for SOX2, Ki67, and nuclei. White arrows indicate proliferating SOX2+ (SOX2+Ki67+) cells (Figure 4C). Scale bar = 20 μm. (FIG. 4D) Percentage fold change of SOX2+ and SOX2+Ki67+ cells by pilocarpine treatment. Data information: (FIG. 4B) SLGs were pooled (10,000 events) from n=3 mice. Data in (FIG. 4D) were calculated from three non-consecutive fluorescent sections of each SLG from n=4 (saline) or n=5 (pilocarpine) mice, are the mean ± SD, and analyzed by Student's t-test. *P=0.0487. [Figure 4B] Same as above. [Figure 4C] Same as above. [Figure 4D] Same as above. [Figure 5A]We show that Sox2 is essential for SLG regeneration after radiation injury. [Figure 5A-5D] Representative images of control (0 Gy, non-IR) and irradiated (10 Gy, IR) SLGs from wild-type (Figure 5A) and Sox2CreERT2;Rosa26mTmG (Figure 5D) mice were shown and analyzed after 1, 3, and 14 days. (Figure 5A-5C) SLGs were stained for neural (TUBB3), SOX2, cyclin DI (CCND1), and nuclei (Figure 5A, 5C), and neural density was calculated (Figure 5B). (Figure 5C) The number of SOX2+ and CCND1+ cells was quantified. (Figure 5D) Sox2CreERT2;Rosa26mTmG mice were followed for 14 days after irradiation (IR) and immunostained for SOX2 (Figure 5D, red). White arrowheads indicate SOX2-negative progeny. Scale bars in (Figures 5A and 5D) are 50 μm. [Figure 5E] Sox2CreERT2;Sox2fl / fl mice and wild-type littermates were irradiated with 10 Gy IR and SLGs were analyzed 13 days later. SLGs were immunostained for SOX2, AQP5, and nuclei. Scale bar = 50 μm. Data information: Data in (Figure 5B) are mean ± SD, n = 3, individual values are plotted. Data in (Figure 5C) are calculated from three non-consecutive fluorescent sections of each SLG from n = 3 mice / treatment, mean ± SD, data were analyzed using one-way ANOVA with post-hoc Dunnett's test. SOX2+(D1)*P=0.0487, SOX2+CCND1+(D3)*P=0.318, SOX2+CCND1+(D7)*P=0.0291. [Figure 5B] Same as above. [Figure 5C] Same as above. [Figure 5D] Same as above. [Figure 5E] Same as above. [Figure 6A]We show that SOX2+ precursors can replenish acinar cells after radiation-induced injury in response to muscarinic stimulation. [Figure 6A] SLGs from Sox2CreERT2;Rosa26mTmG mice were collected after a single 15 Gy dose of IR and explants cultured for 0–48 h. A schematic diagram shows the timing of recombination, culture, and analysis. [Figure 6B] Representative images of lineage-traced explants immunostained for nuclei. Scale bars are 50 μm. [Figure 6C] Quantification of the number of GFP+ cells. Data information: Data in (Figure 6C) were calculated from three random areas of immunostained explants, n=3 for each treatment, individual values were plotted, and data were analyzed using one-way ANOVA with post-hoc Dunnett's test. Error bars indicate mean ± SD. Non-IR vs. IR ***P=0.0022, IR vs. IR+CCh **P=0.0058, IR vs. IR+4-DAMP ***P=0.0010. [Figure 6B] Same as above. [Figure 6C] Same as above. [Figure 7A]We show that acetylcholine / muscarinic signaling maintains SOX2 and the acinar lineage in human SGs. [Figure 7A] Human salivary glands obtained from healthy individuals (non-IR, submandibular glands) or patients undergoing radiotherapy for head and neck cancer (IR) were subjected to qPCR. [Figure 7B-7D] Human SMG explants cultured for 7 days with either mouse embryonic (E)13 parasympathetic ganglia (neural) or E13 mesenchyme (MES). Explants were analyzed by immunostaining for markers of neural (Figure 7B, TUBB3) or cell proliferation (Figure 7C, Ki67) or by qPCR (Figure 7D). Scale bar = 50 μm (Figure 7B, 7C). [Figure 7E] qPCR analysis of adult human salivary gland (SMG or PG) explants of four different individuals cultured for 4 h ± CCh (200 nM, n = 4). Individual datasets are shown in Figure 14D. Data information: Data in (Figure 7A) are n=11 for non-IR and n=7 for IR, ages 30-85 years. Data were normalized to GAPDH, individual values were plotted, and analyzed using Student's t-test with false discovery rate set at 0.05. Error bars indicate mean ± SD. AQP3 P=0.017, MIST1 P=0.086, AMY1 P=0.005, SOX2 P=0.079, CHRM1 P=0.040, CHRM3 P=0.011, EGFR P=0.931, KRT19 P=0.618. Data in (Figure 7D) are mean ± SD for n=2 individuals, solid columns represent individual #1 and dashed columns represent individual #2. Data were normalized to salivary glands of the same individuals cultured with mouse mesenchyme (control, black dashed line). Data in (Figure 7E) are box plots of n=4 different individuals, showing the mean (horizontal line), upper and lower quartiles (boxes) as well as upper and lower values (whiskers). Data were normalized to untreated controls (dashed black line). n=5–8 explants per individual. Data were analyzed using one-way ANOVA with post-hoc Dunnett's test. SOX2 **P=0.00834, CHRM3 *P=0.0449, CHRM1 **P=0.0093, AQP5 **P=0.0069, AQP3 *P=0.0375, MIST1 *P=0.0379, CD44 *P=0.0485, KRT19 *P=0.0461 [Figure 7B] Same as above. [Figure 7C] Same as above. [Figure 7D] Same as above. [Figure 7E] Same as above. [Figure 8A] Short-term ablation of SOX2+ cells reduces acinar cell replacement. (Figure 8A) SOX2+ cells were ablated in the SLG of Sox2CreERT2;Sox2m;Rosa26mTmG / + mice for 3 days and SLGs were analyzed on day 4 (see schematic). Sections of Sox2CreERT2;Sox2fl / fl;Rosa26mTmG / +SLGs were immunostained for SOX2 and myoepithelial cells (a-smooth muscle actin, SMA). Scale bar = 50 pm. (Figure 8B) SOX2+ cells were ablated in the SLG of SOX2CreERT2Rosa26DTA;Rosa26mTmG / + mice for 4 days and SLGs were analyzed on day 5 (see schematic). Sections of Sox2CreERT2Rosa26DTASLG were immunostained for SOX2 and acinar cells (aquaporin 5, AQP5) or subjected to qPCR. Scale bar = 50 pm. Data information: Data in FIG. 8B were normalized to Gapdh and wild type controls. Data are mean ± SD. (n = 1, 3 technical replicates). [Figure 8B] Same as above. [Figure 9A] We show that reinnervation 30 days after transection of the chorda tympani restores the acinar lineage (Figures 9A-9C). SLGs were immunostained for SOX2, TUBB3, AQP5, MIST1 and ECAD (Figure 9A) and the numbers of SOX2+, AQP5+, MIST1+ and KRT8+ cells (Figure 9B), as well as acinar cell size (Figure 9C) were measured 30 days after denervation. n=5 mice per time point per condition. Cells were counted in 3-4 fields per animal. Data information: Data in Figures 9B and 9C, n=5. Data in Figure 9B are mean ± SEM and analyzed using one-way ANOVA, data in Figure 9C are box plots of n=5 mice, showing mean ± SEM and analyzed using Student's f test. *p=0.0498. [Figure 9B] Same as above. [Figure 9C]Same as above. [Figure 10A] We show that SOX2 marks a subset of acinar cells that replenish the acini. [Fig. 10A] Wild-type mouse PG stained for SOX2, ECAD, and nuclei. Scale bar is 50 pm. [Fig. 10B] The percentage of acinar SOX2+ and SOX2- cells that are Ki67+ were counted using FACS and shown as a percentage of total AQP5+SOX2+ or AQP5+SOX2- cells. [Fig. 10C] Percentage of SOX2+ acinar cells that are either cyclin D1+ or cyclin DT. [Fig. 10D] Schematic of Rosa26mTmGCre-mediated gene ablation (adapted from Muzumdar et al., 2007). [Fig. 10E] Representative images of Sox2 lineage-traced SLGs. Cre-mediated recombination was induced in Sox2CreERT2;Rosa26mTmG mice, and SLGs were analyzed 14 or 30 days later by immunostaining for SOX2. Scale bar = 25 μm. [FIG. 10F] Representative images of Kit lineage-traced SLGs and SMGs. Cre-mediated recombination was induced in KitCreERT2;Rosa26mTmG mice, and SMGs / SLGs were analyzed after 14 days and 6 months. Tissues were stained with AQP5 to mark acinar cells and KRT8 to mark intercalated ductal cells. Scale bar = 25 μm. mT = membrane-bound Tomato. Data information: Data in (FIG. 10B), SLGs were pooled from n=2 mice (85,000 events). Data in (FIG. 10C), were calculated from three non-consecutive fluorescent sections of each SLG from n=3 mice, and individual values were plotted. Error bars indicate mean ± SD. [Figure 10B] Same as above. [Figure 10C] Same as above. [Figure 10D] Same as above. [Figure 10E] Same as above. [Figure 10F] Same as above. [Figure 11A]We show that ablation of Sox2 or SOX2+ cells reduces acinar cell replacement despite the presence of nerves. [Figure 11A-11C] Sox2 or SOX2+ cells were ablated in the SLG of Sox2CreERT2;Sox2fl / fl;Rosa26mTmG / + mice (Figure 2A, see schematic) or Sox2CreERT2;Rosa26DTA;Rosa26mTmG / + mice (Figure 2B, see schematic). (Figure 11A, 11B) Sections of SLG of WT, Sox2CreERT2;Sox2fl / fl, and Sox2CreERT2;Rosa26DTA were immunostained for SOX2 or TUBB3 and nuclei. White arrowheads indicate SOX2+ cells. The white dotted squares are enlarged in the right images to highlight that few SOX2+ cells remain in the tissue and non-nuclear (green) staining suggests debris. Scale bar = 50 μm. (FIG. 11C) Raw total density of neurons was calculated using ImageJ. [FIG. 11D] WT or Sox2CreERT2;Sox2fl / fl SLGs were immunostained for cyclin D1 (CCND1) and nuclei. Dashed lines = ducts, arrowheads = CCND1+ acinar cells. Scale bar = 50 μm. Data information: Data in (FIG. 11C), WT n = 4, Sox2fl / fl n = 4, DTA n = 3. Individual values were plotted as mean ± SD and data were analyzed using one-way ANOVA with post-hoc Dunnett's test. **P = 0.0091. Data in (FIG. 11D) are representative images from n = 4 mice. [Figure 11B] Same as above. [Figure 11C] Same as above. [Figure 11D] Same as above. [Figure 12A]We show that transection of the chorda tympani depletes acinar cells at 7 days. (Figures 12A, 12C, 12D, 12G) Control and nerve-transected SLGs were immunostained 7 days after denervation for tyrosine hydroxylase (TH, Figure 12A), SOX2 and TUBB3 (Figure 12C), KRT5 (Figure 12D), caspase-3 (CASP3, Figure 12G), epithelial cells (ECAD), and nuclei. Quantification of acinar cell size in adult wild-type (WT) SLGs with intact or transected chorda tympani (CT) 7 days after denervation (Figure 12B). Scale bars in (Figures 12A, 12C, 12D, 12G) = 25 μm. (FIGS. 12E, 12F) Recombination was induced in Sox2CreERT2;Rosa26mTmG mice 24 hours prior to nerve transection and SLGs were followed for 15 days before immunostaining for TUBB3. The percentage of GFP+ and mT+ acinar cells in control and transected glands is shown in (FIG. 12F). Scale bar (FIG. 12E)=25 μm. (H) Fold change in expression of genes involved in cell cycle and apoptosis 7 days after denervation compared to intact controls. Dashed line indicates intact control. Data information: Data for (FIGS. 12B, 12F, and 12H), n=5. Data for (FIG. 12B) are box plots for n=5 mice, showing the mean (horizontal line), upper and lower quartiles (boxes) as well as upper and lower values (whiskers) and analyzed using Student's t-test. ***P=0.00000347. Data in (Figure 12F) are means ± SD and analyzed by Student's t-test. %GFP+ ***P=0.0000208, %mT+ ***P=0.0000208. Data in (Figure 12H) were normalized to Rsp18 and intact controls (dashed lines). Ccndl *P=0.0477. [Figure 12B] Same as above. [Figure 12C] Same as above. [Figure 12D] Same as above. [Figure 12E] Same as above. [Figure 12F] Same as above. [Figure 12G] Same as above. [Figure 12H] Same as above. [Figure 13A]We show that IR induces cell damage as well as neuronal loss, and that SOX2 and SOX2+ precursors can replenish mouse acinar cells in response to cholinergic mimetics. [Figure 13A], [Figure 13B] Mouse SLGs were analyzed for transcriptional changes by qPCR at days 0, 1, 3, and 7 after 10 Gy of IR. [Figures 13C-13E] Sox2CreERT2;Rosa26mTmG mouse SLG explants were cultured ex vivo for 48 h and immunostained for smooth muscle actin (SMA, Figure 13C), SOX2 (Figure 13D) or Ki67 (Figure 13E) and nuclei. Recombination was induced 24 h before harvesting SLGs for culture. Scale bar = 50 μm. Data information: Data in (Figures 13A and 13B) were normalized to Rsp29 and day 0 controls. Data (n=3 per time point) in (Figures 13A and 13B) are means±SEM and were analyzed using one-way ANOVA with post-hoc Dunnett's test. Bax(D1)**P=0.00826, Bax(D3)**P=0.0871, Pmaipl(D3)*P=0.0369, p21(D3) *P=0.0481, p53(D1)*P=0.0337, MKi67(D1)*P=0.0319, Sox2(D1)**P=0.0072, Sox2(D3)*P=0.0418, Aqp5(D1)*P=0.0421, Misti(D1)*P=0.0432, Tubb3(D1) *P=0.0467, Tubb3(D3)*P=0.0470, Tubb3(D7)*P=0.0489, Vip(D1)*P=0.0402. Images in (FIGS. 13C, 13D, and 13E) are representative of three experiments, n=3, SLG sections per experiment. [Figure 13B] Same as above. [Figure 13C] Same as above. [Figure 13D] Same as above. [Figure 13E] Same as above. [Figure 14A]We show that muscarinic activation is sufficient to increase SOX2 expression and acinar lineage in human adult salivary glands. [Figure 14A] Human salivary glands obtained from healthy individuals (non-IR, submandibular glands) or patients undergoing radiotherapy for head and neck cancer (IR) were subjected to qPCR. [Figure 14B] Representative images of adult human (h) salivary glands (non-IR, 22–31 years old, SMG) immunostained for endogenous SOX10, MIST1, EGFR, CD44, KRT7, AQP3, KRT5, ECAD, and nuclei. Single-headed arrowheads indicate acinar and ductal cells expressing SOX10. Scale bar = 50 μm. [Figure 14C] Quantification of the number of Ki67+ cells in neural cocultures (representative images shown in Figure 7C). [Figure 14D] Adult human salivary gland explants (SMG or PG) from four individual patients (healthy, non-IR) were cultured with CCh ± 200 nM for 4 h. Pooled data presented in Figure 7E. Data information: Data in (Figure 14A) are n=11 for non-IR and n=7 for IR, ages 30-85 years. Data were normalized to GAPDH, individual values were plotted, and analyzed using Student's t-test with false discovery rate set at 0.05. Error bars indicate mean ± SD. TUBB3 P=0.346, VIP P=0.461, GFRA P=0.002, TH P=0.433. Data in (Figure 14C) are n=3, mean ± SEM, and analyzed using Student's t-test. *P=0.0151. Data in (FIG. 14D) (n=4 separate individuals) were normalized to GAPDH expression and salivary glands from the same individuals cultured without CCh (control, black dashed line), run in triplicate, and presented as mean ± SD. [Figure 14B] Same as above. [Figure 14C] Same as above. [Figure 14D-1] Same as above. [Figure 14D-2] Same as above. [Figure 15A]Figure 15 shows that intraglandular injection of cevimeline promotes acinar cell proliferation in mouse salivary glands. Mice were intraglandularly injected with cevimeline (CV) or saline (S, control). Mice were sacrificed 18 hours later and proliferating cells were quantified from tissue sections (3 sections / gland, 3 mice / treatment). Scale bar = 60 pm (representative images shown in Figure 15A, plot comparing % acinar cells of cevimeline treatment vs saline shown in Figure 15B). [Figure 15B] Same as above. [Figure 16A] Figure 16 shows the physical degradation of oxidized alginate (OA) hydrogels. (Figure 16A) Effect of oxidation on physical degradation, wt% was held constant at 5 wt%. (Figure 16B) Effect of wt% on physical degradation, OA% was held constant at 2% OA. (Figure 16C) In vitro vs in vivo degradation of 2% OA at 5 wt%. (Figure 16D) Stability of 2% OA at 5 wt% under refrigeration (4°C) vs freezing (-20°C). [Figure 16B] Same as above. [Figure 16C] Same as above. [Figure 16D] Same as above. [Figure 17A] Figure 17 shows cevimeline release from oxidized alginate (OA) hydrogels. (Figure 17A) Effect of oxidation on cevimeline release, wt% was held constant at 5 wt%. (Figure 17B) Effect of wt% on cevimeline, OA% was held constant at 2% OA. (Figure 17C) Effect of increasing initial drug loading of cevimeline on release kinetics from 2% OA hydrogels at 5 wt%. (Figure 17D) Cevimeline release per hour from 2% OA hydrogels at 5 wt% with different initial cevimeline concentrations. [Figure 17B] Same as above. [Figure 17C] Same as above. [Figure 17D] Same as above. [Figure 18A]Figure 18 shows that cevimeline release from bulk alginate promotes glandular cell proliferation for 3 days. Alginate (ALG, 5% wt:2% OA) or alginate + cevimeline (ALG+CV) was injected immediately adjacent to the salivary gland (Figure 18A). Red circles highlight the alginate after injection. At 3 days, mice were sacrificed and proliferating Ki67+ and EdU+ cells were quantified (Figure 18B and Figure 18C, 3 sections / gland, 3-4 mice / treatment). Student's t-test comparing +CV to ALG control, *p<0.05. Scale bar=40 pm. [Figure 18B] Same as above. [Figure 18C] Same as above. [Figure 19A] We show that alginate with or without cevimeline promotes a pro-repair inflammatory response 7 days after injection. Alginate (ALG, 5% wt:2% OA) or alginate + cevimeline (ALG+CV) was injected immediately adjacent to the salivary gland. Mice were sacrificed on day 7. Salivary gland tissue sections were immunostained for CD3+ T cells (Figures 19A and 19B), CD68+ macrophages (Figures 19C and 19D), or CD206+ repair macrophages (Figure 19E) and nuclei. Macrophage density was quantified and compared to age-matched saline-injected animals (i.p.) or 22-month-old mice (3 sections / gland, 3-4 mice / treatment). One-way ANOVA test comparing +CV vs ALG control vs control, *p<0.05, **p<0.01, ****p<0.00001. Scale bar = 40 pm. [Figure 19B] Same as above. [Figure 19C] Same as above. [Figure 19D] Same as above. [Figure 19E] Same as above. [Figure 20A]We show that cevimeline promotes acinar cell proliferation after radiation-induced injury. (Figure 20A) Schematic of radiation treatment. (Figure 20B) Citrate-stimulated saliva secretion is reduced in 6-8 week old C57 / BL6 female mice 13 days after receiving a 10 Gy dose of radiation. (Figures 20C-20F) 14 days later, animals were injected intraperitoneally (Figures 20B and 20D) or intraglandularly with saline or 10 mg / kg cevimeline (Figures 20C and 20D). Animals were euthanized 18 hours after injection for tissue processing and immunofluorescence. Quantification of proliferation and SOX2+ cells was performed from tissue sections (3 sections per animal). [Figure 20B] Same as above. [Figure 20C] Same as above. [Figure 20D] Same as above. [Figure 20E] Same as above. [Figure 20F] Same as above. [Figure 21A] We show that treatment of irradiated salivary glands with alginate + cevimeline promotes acinar cell proliferation and improves saliva flow rate. [Figure 21A] Schematic diagram of mouse treatment timeline. 14 days after radiation, mice were injected with alginate or alginate + cevimeline and sacrificed on day 3 for proliferation analysis. [Figure 21B] Shows that alginate + cevimeline increased the proliferation rate above the level of alginate alone. [Figure 21C] Compares the percentage of epithelial cells after treatment with alginate + cevimeline compared to alginate alone. [Figure 21D] Shows that saliva was measured 1 day before and 7 days after subcutaneous injection of saline, alginate, or alginate + cevimeline 13 days after radiation. Two-way ANOVA, no RM, p=0.0244, for time parameter. [Figure 21B] Same as above. [Figure 21C] Same as above. [Figure 21D] Same as above. [Figure 22] 1 shows no increase in proliferation with increasing cevimeline. Mice were delivered with 10 mg or 25 mg / kg of alginate and proliferating (Ki67+) acinar cells were quantified on day 3. [Figure 23] 1 shows that alginate promotes acinar cell proliferation. [Figure 24] We show that alginate, with or without cevimeline, does not adversely affect the health of mice. [Diagram 25] 13C nuclear magnetic resonance (NMR) spectrum for analyzing the oxidation efficiency of alginate. 3-(trimethylsilyl)propionic acid-d4 sodium salt (0.05 w / v%) was used as an internal standard. [Figure 26] A pair of syringes for producing injectable hydrogels is shown: the syringe containing the calcium crosslinking solution for producing the hydrogel is connected via a Luer lock to a second syringe containing a solution of alginate and a neurotransmitter mimetic (e.g., a cholinergic and / or muscarinic agonist). [Figure 27A] The location of the canine and human salivary glands is shown. 1.5 ml to 2 ml of alginate hydrogel can be injected directly into the submandibular gland in either human or canine subjects. [Figure 27B] Same as above. [Figure 28] Dog and human salivary glands are similar. The dog and human parotid and sublingual glands appear to be the most similar. The dog submandibular gland is similar to the human in that it is a mixed cell gland. [Figure 29] 1 shows the injection of alginate hydrogel into the submandibular gland of a dog. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] Compositions, methods, and kits are provided for salivary gland regeneration by promoting replacement of acinar cells. The inventors have demonstrated that SOX2 in adult salivary glands +We have shown that progenitor cells, including acinar progenitor cells, are essential for the replenishment of acinar cells with the unexpected ability to repopulate tissues after radiation-induced damage (Example 1). We further showed that cholinergic nerves play a crucial role in controlling the replacement of acinar cells during homeostasis, and the effect of these nerve cells can be reproduced by adding a cholinergic mimetic to acinar progenitor cells. Thus, the SOX2 in tissues + Direct targeting of progenitor cells, including acinar progenitor cells, with cholinergic and / or muscarinic agonists can regenerate the secretory portion of the salivary gland to provide restoration of functional salivary acini and treat oral disorders such as xerostomia following radiation therapy or associated with Sjögren's syndrome. In particular, formulations including muscarinic agonists such as cevimeline encapsulated in alginate hydrogels can be formulated for local administration to the salivary glands and used in the treatment of xerostomia (Example 2).
[0033] Before the present compositions, methods, and kits are described, it is to be understood that this invention is not limited to the particular methods or compositions described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0034] Where a range of values is provided, it is understood that each intervening value between the upper and lower limits of that range, to one tenth of the unit of the lower limit, is also specifically disclosed, unless the context clearly dictates otherwise. Each smaller range between any stated value or intervening value within a stated range and any other stated value or intervening value within that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may be independently included or excluded in the range, and each range in which either, neither, or both limits are included in the smaller range is also encompassed within the invention, subject to any specifically excluded limits in the stated range. Where a stated range includes one or both of the limits, ranges excluding either or both of those included limits are likewise encompassed within the invention.
[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.Any method and material similar or equivalent to the method and material described herein can be used to carry out or test this invention, but some potential and preferred methods and materials are described here.All publications mentioned herein are incorporated by reference to disclose and describe the method and / or material in connection with which the publication is cited.In case of discrepancy, it should be understood that the present disclosure takes precedence over any disclosure of the incorporated publication.
[0036] As will be apparent to one of ordinary skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the invention. Any described method can be carried out in the order of events described or in any other order which is logically possible.
[0037] It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to "a cell" includes a plurality of such cells, and a reference to "the agonist" includes a reference to one or more agonists and equivalents thereof, e.g., ligands and activators known to those skilled in the art.
[0038] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such publications by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
[0039] definition The term "about" is meant to encompass a deviation of plus or minus 5%, particularly with respect to a given amount.
[0040] The term "agent" refers to any material that can be used to prepare pharmaceutical and diagnostic compositions, or which may be compounds such as small synthetic or naturally occurring organic compounds, nucleic acids, polypeptides, antibodies, fragments, isoforms, variants, or other materials that can be used independently for such purposes, all in accordance with the present invention.
[0041] The term "agonist" refers to a substance that binds to a particular receptor and causes a response within the cell. It mimics the action of an endogenous ligand (such as a hormone or neurotransmitter) that binds to the same receptor. A "full agonist" binds to (has affinity for) a receptor, activates the receptor, and exhibits full efficacy at that receptor. An example of a drug that acts as a full agonist is isoproterenol, which mimics the action of acetylcholine at the beta-adrenergic receptor. A "partial agonist" (such as buspirone, aripiprazole, buprenorphine, or norclozapine) also binds to and activates a given receptor, but has only partial efficacy at the receptor compared to a full agonist.
[0042] A "partial agonist" may also be considered a ligand that exhibits both agonist and antagonist effects; when both a full agonist and a partial agonist are present, the partial agonist actually acts as a competitive antagonist, competing with the full agonist for receptor occupancy, resulting in a net decrease in receptor activation observed with the full agonist alone. A "co-agonist" cooperates with another co-agonist to produce a desired effect together. Antagonists block the activation of the receptor by an agonist. Receptors can be activated or inactivated by either endogenous (such as hormones and neurotransmitters) or exogenous (such as drugs) agonists and antagonists, resulting in a stimulated or inhibited biological response. Ligands can act simultaneously as agonists and antagonists at the same receptor, depending on the effector pathway.
[0043] The efficacy of an agonist is usually determined by its EC 50 It is defined by the EC value, which can be calculated for a given agonist by determining the concentration of agonist required to elicit half of the agonist's maximal biological response. 50 Determining EC values is useful for comparing the potency of drugs with similar efficacy that produce physiologically similar effects. 50 The lower the agonist's potency, the lower the drug concentration required to elicit a maximal biological response.
[0044] As used herein, a "biocompatible matrix" refers to a material suitable for implantation into a subject that can be used to encapsulate one or more cholinergic and / or muscarinic agonists or onto which a cell population can be deposited. The biocompatible matrix does not cause toxic or harmful effects once implanted into a subject. In one embodiment, the biocompatible matrix is a polymer with a surface that can be molded into the desired structure that requires repair or replacement. The polymer can also be molded into a portion of the structure that requires repair or replacement. In another embodiment, the biocompatible matrix linearly deforms to fill and distribute throughout the salivary gland. The biocompatible matrix can provide sustained release of one or more cholinergic and / or muscarinic agonists and also provide a supportive framework that allows cells to attach and grow thereon. In some embodiments, the cultured cell population is grown on a biocompatible matrix that provides the appropriate interstitial distance required for cell-cell interactions.
[0045] As used herein, the terms "differentiate", "differentiation", "transdifferentiate", or "transdifferentiation" generally refer to the process by which precursor or progenitor cells differentiate into specific cell types. The terms may refer to the process by which acinar progenitor cells, such as SOX2 expressing acinar progenitor cells, become differentiated acinar cells. Differentiated cells can be identified by patterns of gene expression and cell surface protein expression. As used herein, the term "differentiate" refers to having a different character or function from the original type of tissue or cell. Thus, "differentiation" is the process or behavior of differentiating.
[0046] The terms "modulation" or "modulate" or "modulating" refer to the upregulation (i.e., activation or stimulation), downregulation (i.e., inhibition or suppression), or a combination or dissociation of the two, of a response, such as the ability to change the activity of a protein, a nucleic acid encoding a protein, a pathway, a protein within a pathway, etc., by either upregulation or downregulation.
[0047] The phrase "oral tissue cells" refers to any cell population derived from the mouth. These include one or more different cell types that can be isolated from salivary gland, submandibular gland, sublingual gland, lingual gland, labial gland, buccal gland, palatine gland, striate duct, excretory duct, dental pulp tissue, dentin, periodontium, bone, cementum, gingival submucosa, oral submucosa, tongue and taste bud tissue. In a preferred embodiment, the oral tissue cells are derived from salivary gland. Examples of oral tissue cells include, but are not limited to, myoepithelial cells, epithelial cells, etc.
[0048] The phrase "oral tissue" refers to any collection of cells that form a structure in the mouth. By way of example only, oral tissue includes salivary glands, submandibular glands, sublingual glands, lingual glands, labial glands, buccal glands, palatine glands, striate ducts, excretory ducts, dental pulp tissue, dentin, periodontal tissue, bone, cementum, gingival submucosa, oral submucosa, tongue, and taste bud tissue. In a preferred embodiment, the oral tissue is a salivary gland. The phrase also refers to a portion of an oral tissue, such as a portion of a salivary gland.
[0049] The phrase "oral tissue construct" refers to a substrate seeded with oral tissue cells, preferably a biocompatible substrate, to which the cells attach, grow, proliferate, differentiate, and engraft. The phrase also refers to neomorphic structures that represent early stages of oral tissue development.
[0050] The phrase "salivary gland construct" refers to a substrate seeded with salivary gland cells, preferably a biocompatible substrate, to which the cells attach, grow, proliferate, differentiate, and engraft. The phrase also refers to neomorphic structures that represent early stages of salivary gland development.
[0051] The phrase "oral disorder" refers to a disease or disorder that affects the mouth. In particular, a disease or disorder that affects the production of saliva. Examples of oral disorders include, but are not limited to, salivary gland tumors, cystic fibrosis, Sjogren's syndrome, sialadenitis, parotitis, sialoangitis, sialodochitis, sialolithiasis, sialodocholithiasis, mucocele, ranula, hyposecretion, hypersalivation, sialorrhea, xerostomia, benign lymphoepithelial lesions of the salivary glands, sialectasia, sialosis, stenosis of salivary duct, and stricture of salivary duct.
[0052] The term "treatment" or "treating" refers to therapy, prevention and prophylaxis, and in particular to administering a drug or performing a medical procedure on a patient for prophylaxis (prevention) or to cure or reduce the degree or likelihood of occurrence of a condition or disease or pathology or event. Treatment using the agents described herein may be provided to stimulate or promote regeneration of the salivary glands and / or replacement of acinar cells in the salivary glands.
[0053] The terms "individual," "subject," and "patient" are used interchangeably herein and refer to any member of the subphylum Chordata, including, but not limited to, humans and other primates, including non-human primates such as chimpanzees and other apes, and monkey species; farm animals such as cows, sheep, pigs, goats, and horses; domestic mammals such as dogs and cats; laboratory animals, including rodents such as mice, rats, and guinea pigs; birds, including chickens, turkeys, and other poultry birds, domestic birds such as ducks, geese, wild birds, and game birds. In some cases, the methods of the invention are used in laboratory animals, in veterinary applications, and in the development of animal models for disease, including, but not limited to, rodents, primates, including mice, rats, and hamsters, and transgenic animals.
[0054] A "therapeutically effective dose" or "therapeutic dose" is an amount sufficient to produce a desired clinical result (i.e., achieve therapeutic efficacy). A therapeutically effective dose can be administered in one or more administrations.
[0055] By "therapeutically effective dose or amount" of a composition comprising a cholinergic agonist (e.g., acetylcholine or carbachol) and / or a muscarinic agonist (e.g., cevimeline encapsulated in a hydrogel) is intended an amount that, when administered as described herein, results in a positive therapeutic response, such as improved recovery from xerostomia. Improved recovery may include improved salivary gland function, and increased saliva production and saliva flow rate. Additionally, a therapeutically effective dose or amount may stimulate proliferation of acinar cells and acinar cell precursors, resulting in repopulation of the salivary glands with acinar cells. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular drug or drugs used, the mode of administration, and the like. The appropriate "effective" amount in any individual case may be determined by one of skill in the art using routine experimentation, based on the information provided herein. A therapeutically effective dose may be administered in one or more administrations.
[0056] The phrase "pharmacologically acceptable" refers to molecular entities and compositions that are physiologically tolerated when administered to humans (or non-human animals in the case of veterinary use) and typically do not produce allergic or similar adverse reactions, such as acute gastric upset, dizziness, etc. Preferably, as used herein, the term "pharmacologically acceptable" means approved by a federal or state government regulatory agency or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, particularly humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water or aqueous saline and aqueous dextrose and glycerol solutions are preferably used as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.
[0057] By "pharmaceutically acceptable excipient" is meant an excipient that is generally safe, non-toxic, and useful in preparing the desired pharmaceutical composition, and includes excipients acceptable for veterinary and human pharmaceutical use. Such excipients can be solid, liquid, semi-solid, or, in the case of an aerosol composition, gaseous.
[0058] "Pharmaceutically acceptable salt" includes, but is not limited to, salts prepared with inorganic acids such as amino acid salts, chlorides, sulfates, phosphates, diphosphates, bromides and nitrates, or salts prepared from the corresponding inorganic acid forms of any of the above, for example, salts such as hydrochlorides, or salts prepared with organic acids such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts.Similarly, salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium and ammonium (including substituted ammonium).
[0059] As used herein, the term "contrast agent" refers to a substance that improves contrast for medical imaging of a target tissue, fluid, or structure (e.g., salivary glands) within a subject's body. Exemplary contrast agents include ultrasound contrast agents (e.g., SonoVue microbubbles with sulfur hexafluoride, Optison microbubbles with an albumin shell and an octafluoropropane gas core, Levovist microbubbles with a lipid / galactose shell and an air core, Perflexan lipid microspheres with perfluorocarbon microbubbles, and Perflutren lipid microspheres with octafluoropropane encapsulated in an outer lipid shell), magnetic resonance imaging (MRI) contrast agents (e.g., gadodiamide, gadobenic acid, gadopentetic acid, gadoteridol, gadofosveset, gadoversetamide, gadoxetic acid), and other imaging agents, such as, for example, conjugates. radiological contrast agents for computed tomography (CT), radiography, or fluoroscopy (e.g., diatrizoic acid, metrizoic acid, iodamide, iothalamic acid, ioxithalamic acid, ioglycinic acid, acetolyzoic acid, iocarminic acid, methiodal, diodon, metrizamide, iohexol, ioxaglic acid, iopamidol, iopromide, iotrolan, ioversol, iopentol, iodixanol, iomeprol, iobitridol, ioxilan, iodoxamic acid, iotroxic acid, ioglycamic acid, adipiodone, iobenzamic acid, iopanoic acid, iosetamic acid, ipodate sodium, tyropanoic acid, and ipodate calcium).
[0060] Salivary gland regeneration by promoting replacement of acinar cells Compositions and methods are provided for regeneration of salivary glands by promoting replacement of acinar cells. Regeneration of salivary glands may result in permanent relief of xerostomia. The autonomic nervous system innervates the salivary glands, myoepithelium, blood vessels and interposed duct cells. Salivary acinar cells secrete most of the fluid, electrolytes and proteins in saliva. Neurotransmitter receptors are present on the basolateral membrane of acinar cells with a-adrenergic, β-adrenergic, M3 muscarinic and cholinergic substance P receptors. The primary pathway of protein exocytosis occurs via activation of β-adrenergic receptors (sympathetic pathway), whereas the primary stimulation of fluid secretion occurs via activation of M3 muscarinic receptors (parasympathetic pathway).
[0061] SOX2 in adult salivary glands + It was found that progenitor cells, including acinar progenitors, are essential for the replenishment of acini with an unexpected ability to repopulate tissues after radiation-induced damage. It was also found that cholinergic nerves play a pivotal role in controlling acinar cell replacement during homeostasis, and this neuronal influence can be reproduced by adding cholinergic mimetics to acinar progenitors. Thus, by directly targeting acinar progenitors in tissues with cholinergic and / or muscarinic agonists, or by isolating and expanding acinar progenitors for transplantation and activation with cholinergic and / or muscarinic agonists, the secretory portion of the salivary gland can be regenerated to provide restoration of functional salivary acini and treat oral disorders such as xerostomia after radiation therapy or associated with Sjögren's syndrome. Such a strategy may be applicable to the repair of multiple organ systems, since given organs, such as the intestine, glandular stomach, trachea, and taste buds, express SOX2, are strongly innervated by the autonomic nervous system, and are damaged by therapeutic radiation to eliminate cancer.
[0062] In some embodiments, the method for promoting salivary gland regeneration in a subject in need thereof comprises administering at least one of a cholinergic agent or a muscarinic agent to the glandular progenitor cells of the salivary gland to promote the generation of acinar cells. The cholinergic agent and / or the muscarinic agent can mimic the parasympathetic acetylcholine / muscarinic signaling that has been found to maintain acini in human salivary glands. In some embodiments, one or more cholinergic agents and / or muscarinic agents are administered locally to the salivary gland to promote acinar cell proliferation and increase saliva production.
[0063] In some embodiments, the acinar progenitor cells to which the one or more cholinergic and / or muscarinic agonists are administered are SOX2 + Contains acinar progenitor cells. SOX2 + Acinar progenitor cells are AQP57Ki67 + The endogenous acinar progenitor cells may include cholinesterase and / or mucin (MUC) 19-cells. Exposing endogenous acinar progenitor cells to cholinergic and / or muscarinic agonists causes the acinar progenitor cells to proliferate and develop into secretory acinar cells. Such treatments can be used to repopulate salivary glands with functional secretory acinar cells to treat subjects with oral disorders, such as salivary gland disorders, by, for example, restoring saliva flow rate. Subjects can be monitored after treatment for improvement of salivary gland disorders, and saliva production and secretion.
[0064] In some embodiments, the cholinergic agent can be selected from the group consisting of acetylcholine, bethanechol, carbachol, methacholine, arecoline, nicotine, galantamine, cevimeline, levamisole, muscarine, pilocarpine, donepezil, edrophonium, neostigmine, physostigmine, pyridostigmine, rivastigmine, tacrine, caffeine, huperzine, echothiophate, isoflurophate, cisapride, droperidol, domperidone, metoclopramide, risperidone, and paliperidone.In other embodiments, the cholinergic agent can include at least one of acetylcholine or acetylcholine analogues.For example, the acetylcholine analogue can include carbachol.
[0065] In some embodiments, the muscarinic agonist may include an agonist that activates the muscarinic acetylcholine receptor ("muscarinic receptor"). Muscarinic receptors are divided into five subtypes, named M1-M5. Muscarinic agonists include, but are not limited to, pilocarpine, aceclidine, xanomeline, talsaclidine, sabcomeline, cevimeline, albamerin, arecoline, miramerin, SDZ-210-086, YM-796, RS-86, CDD-0102A (5-[3-ethyl-1,2,4-oxadiazol-5-yl]-1,4,5,6-tetrahydropyrimidine hydrochloride), N-aryl urea-substituted 3-morpholine arecoline, VUO255-035 (N-[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl] -2,1,3-benzothiadiazole-4-sulfonamide), benzyl quinolone carboxylic acid (BQCA), WAY-132983, AFB267B (NGX267), AC-42, AC-260584, chloropyrazines (including but not limited to L-687, 306, L-689-660, 77-LH-28-1, and LY593039), and any quiniclidine ring with one or more carbon substitutions, including substituted nitrogen(s) and / or oxygen(s), particularly including esters, sulfur, or 5- or 6-carbon ring structures; or Any pharma- ceutically acceptable salts, esters, analogs, prodrugs, or derivatives thereof. In some embodiments, a muscarinic agonist selective for the M1 and / or M3 muscarinic receptor subtypes, such as cevimeline, is used.
[0066] Cholinergic and / or muscarinic agonists inhibit SOX2 in vivo or ex vivo. + The pharmaceutical composition can be provided to be administered to acinar progenitor cells, including acinar progenitor cells.The pharmaceutical composition can be formulated into various dosage forms.The dosage can be a pharmacologic or therapeutically effective amount for promoting replacement of acinar cells and / or maintenance and survival of acinar progenitor cells.
[0067] The therapeutically effective dosage of the cholinergic and / or muscarinic agonist described herein may be present in various amounts in various embodiments. For example, in some embodiments, the therapeutically effective amount of the cholinergic and / or muscarinic agonist may be present in a range of about 10-1000 mg (e.g., about 20 mg-1,000 mg, 30 mg-1,000 mg, 40 mg-1,000 mg, 50 mg-1,000 mg, 60 mg-1,000 mg, 70 mg-1,000 mg, 80 mg-1,000 mg, 90 mg-1,000 mg, about 10-900 mg, 10-800 mg, 10-700 mg, 10-600 mg, 10-500 mg, 100-1,000 mg, 100-900 mg, 100-800 mg, 100-700 mg, 10 ...600 mg, 10-800 mg, 10-900 mg, 100-800 mg, 100-700 mg, 100-600 mg, 10-1000 mg, 100-1000 mg, 100-1000 mg, 100-1000 mg, 100-1000 mg, 100-1000 mg, 100-1000 mg, 100-1000 mg, 100-1000 mg, 100-1000 mg, 10 The amount may be in the range of 00-500mg, 100-400mg, 100-300mg, 200-1000mg, 200-900mg, 200-800mg, 200-700mg, 200-600mg, 200-500mg, 200-400mg, 300-1000mg, 300-900mg, 300-800mg, 300-700mg, 300-600mg, 300-500mg, 400mg-1,000mg, 500mg-1,000mg, 100mg-900mg, 200mg-800mg, 300mg-700mg, 400mg-700mg, and 500mg-600mg). In some embodiments, the 15-PGDH inhibitor is present in an amount of about 10 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg or more. In some embodiments, the 15-PGDH inhibitor is present in an amount of about 1000 mg, 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 450 mg, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 150 mg, or 100 mg or less.
[0068] In other embodiments, a therapeutically effective dosage of a cholinergic agonist and / or a muscarinic agonist may be, for example, from about 0.001 mg / kg body weight to 500 mg / kg body weight, e.g., from about 0.001 mg / kg body weight to 400 mg / kg body weight, from about 0.001 mg / kg body weight to 300 mg / kg body weight, from about 0.001 mg / kg body weight to 200 mg / kg body weight, from about 0.001 mg / kg body weight to 100 mg / kg body weight, from about 0.001 mg / kg body weight to 90 mg / kg body weight, from about 0.001 mg / kg body weight to 80 mg / kg body weight, from about 0.001 mg / kg body weight to 100 mg / kg body weight, from about 0.001 mg / kg body weight to 150 mg / kg body weight, from about 0.001 mg / kg body weight to 200 mg / kg body weight, from about 0.001 mg / kg body weight to 300 mg / kg body weight, from about 0.001 mg / kg body weight to 400 mg / kg body weight, from about 0.001 mg / kg body weight to 500 mg / kg body weight, from about 0.001 mg / kg body weight to 500 mg / kg body weight, from about 0.001 mg / kg body weight to 600 mg / kg body weight, from about 0.001 mg / kg body weight to 100 mg / kg body weight, from about 0.001 mg / kg body weight to 200 mg / kg body weight, from about 0.001 mg / kg body weight to 300 mg / kg body weight, from about 0.001 mg / kg body weight to 400 mg / kg body weight, from about 0.001 mg / kg body weight to 5 It may be about 0.001 mg / kg body weight to 70 mg / kg body weight, about 0.001 mg / kg body weight to 60 mg / kg body weight, about 0.001 mg / kg body weight to 50 mg / kg body weight, about 0.001 mg / kg body weight to 40 mg / kg body weight, about 0.001 mg / kg body weight to 30 mg / kg body weight, about 0.001 mg / kg body weight to 25 mg / kg body weight, about 0.001 mg / kg body weight to 20 mg / kg body weight, about 0.001 mg / kg body weight to 15 mg / kg body weight, or about 0.001 mg / kg body weight to 10 mg / kg body weight.
[0069] In yet other embodiments, the therapeutically effective dosage of the cholinergic and / or muscarinic agonist is, for example, about 0.0001 mg / kg body weight to 0.1 mg / kg body weight, e.g., about 0.0001 mg / kg body weight to 0.09 mg / kg body weight, about 0.0001 mg / kg body weight to 0.08 mg / kg body weight, about 0.0001 mg / kg body weight to 0.07 mg / kg body weight, about 0.0001 mg / kg body weight to 0.06 mg / kg body weight, about 0.0001 mg / kg body weight to 0.05 mg / kg body weight, about 0.0001 mg / kg body weight to 0.06 mg / kg body weight, about 0.0001 mg / kg body weight to 0.07 ... 0.05mg / kg body weight, about 0.0001mg / kg body weight to about 0.04mg / kg body weight, about 0.0001mg / kg to 0.03mg / kg body weight, about 0.0001mg / kg to 0.02mg / kg body weight, about 0.0001mg / kg to 0.019mg / kg body weight, about 0.0001mg / kg to 0.018mg / kg body weight, about 0.0001mg / kg to 0.017mg / kg body weight, about 0.0001mg / kg to 0.016mg / kg body weight , about 0.0001mg / kg body weight to 0.015mg / kg body weight, about 0.0001mg / kg body weight to 0.014mg / kg body weight, about 0.0001mg / kg body weight to 0.013mg / kg body weight, about 0.0001mg / kg body weight to 0.012mg / kg body weight, about 0.0001mg / kg body weight to 0.011mg / kg body weight, about 0.0001mg / kg body weight to 0.01mg / kg body weight, about 0.0001mg / kg body weight to 0.009mg / kg body weight, It may be about 0.0001 mg / kg body weight to 0.008 mg / kg body weight, about 0.0001 mg / kg body weight to 0.007 mg / kg body weight, about 0.0001 mg / kg body weight to 0.006 mg / kg body weight, about 0.0001 mg / kg body weight to 0.005 mg / kg body weight, about 0.0001 mg / kg body weight to 0.004 mg / kg body weight, about 0.0001 mg / kg body weight to 0.003 mg / kg body weight, or about 0.0001 mg / kg body weight to 0.002 mg / kg body weight.
[0070] In some embodiments, a therapeutically effective dose is 0.0001 mg / kg body weight, 0.0002 mg / kg body weight, 0.0003 mg / kg body weight, 0.0004 mg / kg body weight, 0.0005 mg / kg body weight, 0.0006 mg / kg body weight, 0.0007 mg / kg body weight, 0.0008 mg / kg body weight, 0.0009 mg / kg body weight, 0.001 mg / kg body weight, 0.002 mg / kg body weight, 0.003 mg / kg body weight, 0.004 mg / kg body weight, The effective dose for a particular individual may be 0.005 mg / kg body weight, 0.006 mg / kg body weight, 0.007 mg / kg body weight, 0.008 mg / kg body weight, 0.009 mg / kg body weight, 0.01 mg / kg body weight, 0.02 mg / kg body weight, 0.03 mg / kg body weight, 0.04 mg / kg body weight, 0.05 mg / kg body weight, 0.06 mg / kg body weight, 0.07 mg / kg body weight, 0.08 mg / kg body weight, 0.09 mg / kg body weight, or 0.1 mg / kg body weight. The effective dose for a particular individual may vary (e.g., increase or decrease) over time, depending on the needs of the individual.
[0071] In some embodiments, a therapeutically effective dosage of a cholinergic and / or muscarinic agonist can be a dosage of 10 pg / kg / day, 50 pg / kg / day, 100 pg / kg / day, 250 pg / kg / day, 500 pg / kg / day, 1000 pg / kg / day or more. In various embodiments, the amount of cholinergic and / or muscarinic agonist is sufficient to provide the patient with a dosage of between 0.01 pg / kg and 10 pg / kg, between 0.1 pg / kg and 5 pg / kg, between 0.1 pg / kg and 1000 pg / kg, between 0.1 pg / kg and 900 pg / kg, between 0.1 pg / kg and 900 pg / kg, between 0.1 pg / kg and 800 pg / kg, between 0.1 pg / kg and 700 pg / kg, between 0.1 pg / kg and 600 pg / kg, between 0.1 pg / kg and 500 pg / kg, or between 0.1 pg / kg and 400 pg / kg.
[0072] Various embodiments may include different dosing regimens.In some embodiments, the cholinergic and / or muscarinic agonist can be administered every other month, every month, twice a month, every three weeks, every other week, every week, twice a week, three times a week, every day, twice a day, or another clinically desirable dosing schedule.The dosing regimen for a single subject does not have to be at regular intervals, but can vary over time according to the needs of the subject.
[0073] Depending on the subject to be treated, the mode of administration, and the type of treatment desired, e.g., prevention, prophylaxis, therapy, the compositions are formulated in a manner consistent with these parameters. A summary of such techniques is found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, Pa.
[0074] The preparation of therapeutic compositions containing small organic molecule polypeptides, analogs, or active fragments as active ingredients is well understood in the art. The compositions of the present invention can be administered parenterally, topically, or via implanted reservoirs. Such compositions can be prepared as injectables, either as liquid solutions or suspensions, but solid forms suitable for solution or suspension in liquid prior to injection can also be prepared. Preparations can also be emulsified. The active therapeutic ingredient is often mixed with an excipient that is pharma- ceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, and the like, and combinations thereof. Formulations generally include a diluent, and optionally adjuvants, buffers, preservatives, and the like. In addition, if desired, the composition can contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and the like, which enhance the effectiveness of the active ingredient.
[0075] The composition can also be administered locally to the target site using various techniques known to those skilled in the art. For example, these can include sprays, lotions, gels, or other vehicles such as alcohol, polyglycols, esters, oils, and silicones. The administration of the compositions described herein can be pharmacokinetically and pharmacodynamically controlled by calibrating various administration parameters, including frequency, dosage, duration mode, and route of administration. Changes in dosage, duration, and mode of administration can also be manipulated to produce the required activity. The therapeutic composition is administered in the form of a unit dose in a conventional manner, for example, by injection of a unit dose, for example, intravenously. The term "unit dose" when used in relation to the therapeutic composition of the present invention refers to a physically discrete unit suitable as a unitary dosage for humans, each unit containing a predetermined amount of active material calculated to produce the desired therapeutic effect in association with the required diluent, i.e., carrier or vehicle.
[0076] The composition can be administered in a manner compatible with the agent, dosage form selected to treat the subject, and in a therapeutically effective amount. When it is desired to achieve a desired effect in vitro, the effective amount of the cholinergic and / or muscarinic agonist can range from about 0.1 nM to about 10 M, more preferably from about 0.1 nM to about 5 M, and most preferably from about 0.1 nM to about 1 M. The desired effect refers to the effect of the agent to promote replacement of acinar cells and / or the maintenance and survival of acinar progenitor cells. The precise amount of active ingredient required to be administered depends on the judgment of the practitioner and is peculiar to each individual.
[0077] The agents described herein may be modified or formulated for administration at the site of the lesion. Such modifications may include, for example, formulations that promote or extend the half-life of the compound or composition in a particular environment. In addition, such modifications may include formulations of the compound or composition to include target proteins or sequences that promote or enhance uptake of the compound / composition into acinar progenitor cells. In certain embodiments, such modifications may increase or decrease the expression of SOX2 in salivary glands compared to other locations or cells. +This results in preferential targeting of the compound to acinar progenitor cells.
[0078] The sterile injectable form of the composition may be an aqueous or oily suspension. The suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as a solvent or suspending medium. For this purpose, any bland fixed oil may be used, including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils such as olive oil or castor oil, especially their polyoxyethylated versions. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, which are commonly used to formulate pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants or bioavailability enhancers, such as Tweens, Spans, and other emulsifiers, commonly used in the manufacture of pharma- ceutically acceptable solid, liquid, or other dosage forms, may also be used for formulation purposes.
[0079] Parenteral formulations can be administered as a single bolus, infusion or loading bolus followed by maintenance doses. These compositions can be administered once a day or "as needed." Pharmaceutical compositions can be orally administered in any orally acceptable dosage form, including capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typically added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. Specific sweetening, flavoring, or coloring agents may also be added as required. Alternatively, pharmaceutical compositions can be administered in the form of suppositories for rectal administration. These can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycols. The pharmaceutical composition of the present invention can also be administered topically. Topical application can be carried out in a rectal suppository formulation (see above) or in a suitable enema formulation. A topical transdermal patch can also be used. For topical application, the pharmaceutical composition can be formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of the present invention include mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water. Alternatively, the pharmaceutical composition can be formulated into a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharma- ceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.
[0080] In some embodiments, the cholinergic and / or muscarinic agonist can be formulated to provide controlled release of the cholinergic and / or muscarinic agonist to endogenous salivary gland acinar precursor cells.Controlled release can include at least one of delayed release, sustained release, gradient release, time release, patterned release, or spatial release.Delayed release, sustained release, gradient release, time release, patterned release, or spatial release are mechanisms used in medicine to allow release of active ingredients over time.The advantage of controlled release formulations is that they are delivered in a defined release pattern less frequently than immediate release formulations of the same active compound.
[0081] A controlled release formulation can be designed to release the active agent at a predetermined rate to maintain a constant drug level for a specified extended period of time, for up to about 1 hour, about 12 hours, about 24 hours, about 2 days, about 3 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks or more, after administration or after a lag period associated with delayed release of the drug. In certain embodiments, the active agent is released over a time interval of about 1 week to about 2 weeks or more. Alternatively, the active agent can be released for at least 1 week, at least 2 weeks, at least 3 weeks, or up to 14 days, up to 20 days, up to 30 days or more. In still other embodiments, the active agent is released over a period of about 1 week to about 3 weeks or more after administration.
[0082] In other embodiments, the cholinergic or muscarinic agonist is provided in a biocompatible carrier, matrix or scaffold that can be administered to a subject. By way of example, the biocompatible substrate can include a polymeric macro- or micro-scaffold and at least one carrier material that is incorporated on or within the polymeric macro- or micro-scaffold. The at least one carrier material, matrix or scaffold can include a material that can carry and differentially and / or controllably release at least one cholinergic or muscarinic agonist to endogenous salivary acinar progenitor cells.
[0083] The carrier, matrix, or scaffold allows for cholinergic and / or muscarinic agonists to be incorporated, and promotes the proliferation of expanded acinar progenitor cells (e.g., SOX2 + The carrier, matrix, or scaffold may be of any material that is compatible with the addition of or in the presence of cells (cells). The carrier, matrix, or scaffold may be primarily non-immunogenic and biodegradable. Examples of biodegradable materials include, but are not limited to, alginate, polyglycolic acid (PGA), polylactic acid (PLA), hyaluronic acid, catgut suture material, gelatin, cellulose, nitrocellulose, collagen, albumin, fibrin, cotton, or other naturally occurring biodegradable materials. It may be preferable to sterilize the matrix or scaffold material prior to administration or implantation, for example, by treatment with ethylene oxide or by irradiation with gamma irradiation or electron beam. Additionally, many other materials can be used to form the scaffold or framework structure, including, but not limited to, nylon (polyamide), Dacron (polyester), polystyrene, polypropylene, polyacrylates, polyvinyl compounds (e.g., polyvinyl chloride), polycarbonate (PVC), polytetrafluoroethylene (PTFE, Teflon®), Thermanox (TPX), polymers of hydroxy acids such as polylactic acid (PLA), polyglycolic acid (PGA), and polylactic-glycolic acid (PLGA), polyorthoesters, polyanhydrides, polyphosphazenes, and various polyhydroxyalkanoates, as well as combinations thereof.
[0084] Suitable matrices include polymer meshes or sponges, and polymer hydrogels. Hydrogels are defined as materials that form when organic polymers (natural or synthetic) are crosslinked through covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure that traps water molecules to form a gel. In general, these polymers are at least partially soluble in aqueous solutions such as water, buffered salt solutions, or aqueous alcohol solutions with charged side groups, or their monovalent ionic salts.
[0085] In some embodiments, the matrix is biodegradable for less than one year, more preferably less than six months, and most preferably over 2-10 weeks. The polymer composition, as well as the method of manufacture, can be used to determine the rate of degradation. For example, mixing increasing amounts of polylactic acid with polyglycolic acid decreases the degradation time. Polyglycolic acid meshes that can be used are commercially available, for example, from surgical supply companies (e.g., Ethicon, NJ).
[0086] For example, a muscarinic agonist can be encapsulated in an alginate hydrogel. In some embodiments, the encapsulated muscarinic agonist is selective for M1 and / or M3 muscarinic receptor subtypes (e.g., cevimeline). In other embodiments, the muscarinic agonist is a non-selective muscarinic agonist (e.g., pilocarpine). The alginate in the hydrogel can be ionically crosslinked with a divalent cation (e.g., see Example 2 for a description of a biodegradable calcium crosslinked alginate hydrogel encapsulating cevimeline). In some embodiments, the concentration of alginate in the hydrogel ranges from about 2 to about 10 weight percent (wt%), including any wt% within this range, e.g., 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 wt%. In some embodiments, the alginate is partially oxidized. For example, about 2% to about 10% of the alginate may be oxidized, including any percentage within this range, such as 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%. In one embodiment, the alginate in the hydrogel is about 2% oxidized and has a concentration of 5% by weight. Such alginate hydrogels can maintain delivery of muscarinic agonists for at least 7 days after administration to a subject (see, for example, Example 2).
[0087] The composition comprising the encapsulated cholinergic and / or muscarinic agonist is suitable for localized delivery to the salivary gland. A physician may, for example, identify the location of the salivary gland to be injected by palpation or medical imaging (e.g., ultrasound, X-ray, or MRI). In some embodiments, a contrast agent is included in the composition comprising the encapsulated cholinergic and / or muscarinic agonist, allowing confirmation of localization of the composition to the salivary gland by medical imaging after administration. In some embodiments, the contrast agent is a microbubble (e.g., for use in ultrasound) or a radiopaque contrast agent (e.g., for use in radiography). The contrast agent may be included in the same composition as the cholinergic and / or muscarinic agonist, or may be included in a different composition, and may be used before or after administration of the cholinergic and / or muscarinic agonist.
[0088] In certain embodiments, the composition is injected into or adjacent to a salivary gland. Salivary glands that may be treated by the subject method include, but are not limited to, parotid, submandibular, and sublingual glands, as well as minor salivary glands, including serous, mucous, or serous mucous salivary glands.
[0089] In some embodiments, the subject to be treated has an oral disorder, such as a disorder that affects the production of saliva. Examples of oral disorders include, but are not limited to, salivary gland tumors, cystic fibrosis, Sjogren's syndrome, sialadenitis, parotitis, sialoangitis, sialodochitis, sialolithiasis, sialodocholithiasis, mucocele, ranula, hyposecretion, hypersalivation, sialorrhea, xerostomia, benign lymphoepithelial lesions of the salivary glands, sialectasia, sialosis, stenosis of salivary duct, and stricture of salivary duct. In other embodiments, the subject may have previously been treated with radiation effective to cause xerostomia. The methods described herein can be used to treat human subjects for such oral disorders that affect the production of saliva (e.g., xerostomia). The methods described herein will also find use in veterinary applications for the treatment of xerostomia in farm animals, including but not limited to, pets such as dogs and cats, and livestock such as sheep, goats, pigs, horses and cows.
[0090] kit Also provided is a kit for treating a subject with xerostomia with at least one of a cholinergic agonist or a muscarinic agonist to promote acinar cell production. The cholinergic agonist and / or the muscarinic agonist may be contained in separate compositions or in the same composition. The kit may include a unit dose, e.g., an injectable dose(s), of a formulation that includes a cholinergic agonist and / or a muscarinic agonist suitable for use in the treatment method described herein. In such a kit, in addition to the container that contains the unit dose, an information package insert is provided that describes the use of the treatment for xerostomia and the associated benefits. The kit may include, for example, a dosage regimen of the cholinergic agonist and / or the muscarinic agonist that is included in the kit.
[0091] Formulations suitable for local administration to the salivary glands are of particular interest, and in such embodiments, the kit may further include one or more syringes or other devices for achieving such administration. In some embodiments, the kit includes a first syringe or device pre-filled with the composition (e.g., a muscarinic agonist such as cevimeline encapsulated in an alginate hydrogel that may be cryopreserved). The kit may further include a second syringe filled with calcium chloride that can be connected to the first syringe via a luer lock. The kit may be used, for example, by thawing the contents of the first syringe (e.g., cevimeline encapsulated in an alginate hydrogel) and mixing it with the contents of the second syringe (e.g., CaCl2, which produces a calcium cross-linked alginate hydrogel that encapsulates the cevimeline) before injecting into the salivary gland. The physician may identify the location of the salivary gland to be injected, for example, by palpation or ultrasound.
[0092] In some embodiments, the kit further comprises a contrast agent that allows confirmation of localization of the composition comprising the muscarinic agonist (e.g., cevimeline encapsulated in an alginate hydrogel) to the salivary gland by medical imaging after administration. In some embodiments, the contrast agent is a microbubble (e.g., for use in ultrasound) or a radiopaque contrast agent (e.g., for use in X-ray imaging). The contrast agent may be contained in the same composition as the muscarinic agonist or in a different composition, and may be added before or after administration of the muscarinic agonist.
[0093] In addition to the above components, the subject kits may further include instructions for carrying out the subject methods (in certain embodiments). These instructions may be present in the subject kits in various forms, one or more of which may be present in the kit. One form in which these instructions may be present is as printed information on a suitable medium or substrate, such as a sheet or sheets of paper on which the information is printed, in the kit packaging, in a package insert, etc. Yet another form in which these instructions may be present is a computer readable medium on which the information is recorded, such as a diskette, a compact disc (CD), a flash drive, etc. Yet another form in which these instructions may be present is a website address that may be used via the Internet to access the information at a remote site.
[0094] Other embodiments described herein will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein.All U.S. patents and other references cited herein are specifically incorporated by reference for any reason.The specification and examples should be considered as merely exemplary, with the true scope and spirit of the invention being indicated by the following claims. EXAMPLES
[0095] The following examples are presented to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent that the following experiments are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric.
[0096] All publications and patent applications cited in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0097] The present invention has been described with respect to specific embodiments found or provided by the inventors to include preferred modes for carrying out the invention. Those skilled in the art will understand in light of this disclosure that numerous modifications and changes can be made in the specific embodiments exemplified without departing from the intended scope of the invention. For example, codon redundancy allows modifications of the underlying DNA sequence without affecting the protein sequence. Biological functional equivalence considerations allow modifications of the protein structure without affecting the biological action in type or amount. All such modifications are intended to be within the scope of the appended claims.
[0098] Example 1 Postirradiation salivary acinar regeneration in response to cholinergic activation via a progenitor cell-dependent mechanism Introduction Therapeutic radiation remains a life-saving treatment for cancer patients and is utilized for a variety of malignancies, including those of the head and neck. Indeed, the majority of patients suffering from head and neck cancer will undergo radiation therapy in addition to chemotherapy and surgery (60,000 new cases per year in the United States; Siegel et al., 2015). Although this combined treatment is highly effective in eliminating the tumor, a severe side effect is the damage and / or destruction of healthy tissues in the area of radiation exposure. Such organs include the salivary glands, which exhibit tissue dysfunction even after low doses of radiation (Grundmann et al., 2009). At the high doses (60 Gy) routinely given to patients, off-target radiation destroys the acinar cells that synthesize saliva (Sullivan et al., 2005; Redman, 2008), resulting in lifelong dry mouth and comorbidities such as dental caries, oral infections, and poor wound healing (Brown et al., 1975; Dreizen et al., 1977; Dusek et al., 1996). Although intensity-modulated radiation to spare one of the three major salivary glands (the parotid) has been successful, the proximity of the gland to the tumor site often precludes application of this technique, and 80% of head and neck cancer patients have dry mouth syndrome (Lee & Le, 2008).
[0099] As with all other organs damaged by radiation, including the lung, heart, and bladder (Emami et al., 1991), few, if any, therapies are available to improve or restore tissue function. Current treatment options for cancer survivors suffering from radiation-induced salivary dysfunction and degeneration focus on short-term relief of symptoms, but long-term restorative therapies are not available. Regenerative strategies such as reactivation of endogenous stem cells or transplantation of non-irradiated stem cells have been proposed (Lombaert et al., 2008; Ogawa et al., 2013; Pringle et al., 2016). However, these applications are limited by the scarce knowledge of the identity of adult salivary progenitor cells that contribute to acini under homeostatic or injury conditions. Although it was recently proposed that acinar cells are derived by self-renewal rather than from defined precursors (Aure et al., 2015), no analysis of subpopulations of these cells for progenitor-like activity was performed. Whether acinar cells can repopulate after genotoxic injury, either through self-renewal or progenitor proliferation, also remains to be determined. Although numerous studies have utilized irradiated salivary glands as models of degeneration (Zeilstra et al., 2000; Coppes et al., 2001, 2002), the regenerative capacity of radiation-damaged adult salivary cells has not been investigated in vivo.
[0100] How acinar cells are replaced during salivary gland homeostasis is poorly understood. Studies of adult organs over the past 150 years have clearly demonstrated that peripheral nerves are essential for maintaining organ and tissue integrity (Erb, 1868). Skeletal muscles atrophy in the absence of motor nerve stimulation (Fu & Gordon, 1995; Batt & Bain, 2013), and epithelial organs such as fungiform taste buds (Von Vintschgau & Honigschmied, 1877), prostate (Wang et al., 1991; Lujan et al., 1998), and salivary glands regress after removal of sensory and / or autonomic nerves (Schneyer & Hall, 1967; Mandour et al., 1977; Kang et al., 2010). How nerves control tissue homeostasis in these organs is unclear, but studies in skin indicate that sensory nerves, through Sonic Hedgehog secretion, promote the self-renewal of adult epithelial stem cells and, consequently, the maintenance of downstream cell lineages in the skin, namely dome cells (Peterson et al., 2015; Xiao et al., 2015). In addition, studies in salamanders (Wallace, 1972) and embryonic salivary glands (Knox et al., 2013) suggest that peripheral nerves have the capacity to regenerate tissues via activation of pluripotent stem cells, although evidence for this in adult mammalian systems is lacking.
[0101] Using a combination of mouse genetics, ex vivo culture, and human tissue explants, we unexpectedly discovered that salivary acini can regenerate after radiation and in response to cholinergic activation via a progenitor cell-dependent mechanism. We show that SOX2 is the only precursor of the acinar lineage capable of replacing acinar cells during homeostasis and after radiation-induced injury, indicating that salivary progenitors can survive genotoxic shock, at least in the short term. Importantly, treatment of healthy and irradiated tissues with cholinergic mimetics stimulated acinar cell replenishment. Thus, our data reveal an extensive regenerative capacity of the tissue even under genotoxic shock and support the role of SOX2 +It has been suggested that cell targeting may be a therapeutic approach to regenerate tissues damaged by radiation therapy.
[0102] result SOX2 marks progenitors that give rise to acinar but not ductal cells during salivary gland homeostasis SOX2 has been established as a progenitor cell marker in fetal mouse mandibular and sublingual salivary glands, but SOX2 in adult tissues + It is unclear whether the cells also give rise to acinar and duct cells (Arnold et al., 2011; Emmerson et al., 2017). Furthermore, it is not known whether these cells are also present in the adult human salivary gland. SOX2 was found to be expressed by a subset of acinar cells in all three of the major adult human salivary glands [Figure 1A, submandibular gland (SMG), sublingual gland (SLG), and parotid gland (PG)]. In mice, SOX2 protein was restricted to adult mouse SLG (absent in SMG and PG, Figures 1B and 10A) and expressed in undifferentiated aquaporin (AQP) 5-positive, mucin (MUC) 19-negative acinar cells (all AQP5 + Consistent with their potential role as progenitor cells, approximately 6% of SOX2 + AQP5 + Cells co-expressed Ki67 (Fig. 1E and 10B), while 19 ± 4% were in the cell cycle (cyclin D1 + , Fig. 10C). SOX2 + To determine whether cells contributed to the acinar and ductal lineages, Rosa26 mTmG Sox2, crossed with a reporter strain CreERT2 Genetic lineage tracing was performed using mice (Arnold et al., 2011). mTmGThe mice, when crossed with a Cre line, are dual fluorescent reporters that express membrane-targeted tandem dimer Tomato (mT) before Cre-mediated excision, and membrane-targeted green fluorescent protein (mG) after excision (Muzumdar et al., 2007, Figure 10D). Thus, lineage-traced cells express mG. As shown in Figure 1F, SOX2 + The cells self-renew after 14 or 30 days and produce differentiated acinar cells marked by AQP5 and MUC19, but not KRT8. + They do not produce ductal cells (Figs 1F and EV1E). Thus, our lineage tracing results suggest that SOX2 + These results suggest that the cells are lineage-restricted progenitors that give rise to differentiated progeny, similar to those observed in the epidermis, gut, and incisors ( Owens & Watt, 2003 ; Barker, 2014 ; Seidel et al., 2017 ).
[0103] KIT mainly exists in the intervening duct between the SLG and SMG + At 6 weeks of age, Rosa26 cells (Andreadis et al., 2006; Nelson et al., 2013) have been previously proposed to give rise to acinar cells in adult tissues (Lombaert et al., 2008; Nanduri et al., 2013, 2014; Pringle et al., 2016). mTmG Kit crossed with reporter CreERT2 These cells were genetically traced using the KIT promoter. + Cell-derived acinar cells (i.e., double positive for AQP5 and mG) were not evident in either the SLG or SMG 14 days or 6 months after induction (Figure 10F). + KIT cells contributed exclusively to the interstitial ducts of the SLG (as can be observed by co-staining for the interstitial duct marker KRT8), as well as to the interstitial ducts and larger ducts in the SMG. Thus, these data support the conclusion that KIT + Cells are ductal and SOX2 + Indicates a precursor of cells.
[0104] SOX2 and SOX2 + Cells are essential for the production of secretory acini Our lineage tracing analysis demonstrated that SOX2 + We confirmed that the cells give rise to acinar cells, but not ductal cells. However, we found that the Ki67 expression level was higher than that of the TA cells, suggesting alternative progenitors for the acinar lineage or transit-amplifying cells (TA cells). + SOX2 - Acinar cells (approximately 6% SOX2 + Ki67 + and 16.5%SOX2 - Ki67 + We also observed the presence of Sox2 CreERT2 ;Sox2 fl / fl SOX2 mice (Figure 2A and 2C) were used + We genetically ablated Sox2 in cells or expressed an inducible Sox2 promoter (Sox2 CreERT2 ;Rosa26 DTA 2B and 2D) using diphtheria toxin (DTA) expressed under the control of SOX2 + SOX2 and SOX2 in SLG maintenance and repair by ablating cells + In the latter assay, we investigated the cellular requirements for SOX2 + Cells undergo cell death in response to intracellular production of DTA. + Depletion of Sox2 from cells or SOX2 via DTA + Cell elimination is driven by SOX2 + and AQP5 + Cells were severely depleted but not KRT8 + This is not the case in ductal cells, but Sox2 and SOX2 are required to maintain functional acini. + These results indicate that the expression of Sox2 or SOX2 + The efficiency of cell elimination is shown in Figure 11A. In the absence of Sox2, cyclin D1 (CCND1) +Acinar cells, but not ductal cells, exited the cell cycle, as indicated by a decrease in acinar cells (Figure (Figure11D; arrowhead indicates CCND1 + The dotted white line highlights ductal cells. + In cell elimination, AQP5 + By day 8, few acini remained, as indicated by extensive areas of the ductal network completely devoid of cells (Figures 2B and 2D, and 11A) (ducts are marked by dashed lines or KRT8 in Figure 2B). To exclude the possibility that tissue degeneration was solely due to tissue destabilization rather than loss of acinar cell replacement, SLGs were examined after short-term removal. As shown in Figure 8, at days 4 or 5 (days 3 or 4 of tamoxifen treatment), Sox2 CreERT2 ;Sox2 fl / fl and Sox2 CreERT2 ;Rosa26 DTA SOX2 in both glands of the SLG + Few cells remained (Figures 8A and 8B), and Sox2 transcripts were substantially reduced (Figure 8B). However, acini were present, albeit disorganized and atrophic in appearance. Furthermore, SOX2 + No increase in Sox2 cells (or Sox2 transcripts) was observed, indicating that SOX2 is not ectopically expressed in acinar cells in response to tissue injury. We also determined whether the changes in tissue composition were due to reduced innervation, an essential regulator of tissue function. However, Sox2 CreERT2 ;Sox2 fl / fl In the SLG, we measured innervation similar to that in wild-type controls, and Sox2 CreERT2 ;Rosa26 DTA In the SLG, we measured a significant increase in axon bundles (Figures 11B and 11C). The latter finding suggests that removal of cells triggers the release of factors that promote innervation, but that regeneration is not possible without SOX2+ cells, even with increased innervation. In summary, these results suggest that, at least under the conditions tested, SOX2 +Our data indicate that SOX2 cells are the only acinar precursors in the SLG and that acini do not arise from self-renewal of fully differentiated acinar cells, as previously suggested (Aure et al., 2015). Similar to studies in the epidermis, gut, and incisors (Owens & Watt, 2003; Barker, 2014; Seidel et al., 2017), our data also support the notion that SOX2 may be involved in the rapid repopulation of the acinar compartment. + This suggests the presence of a cell-derived transit-amplifying (TA) population.
[0105] Parasympathetic nerves are SOX2 + Preserves precursors and promotes acinar cell replacement via SOX2 Adult mouse and human salivary glands atrophy after removal of parasympathetic activity. However, the effects of denervation on acinar cell replacement and progenitor cells have not been investigated (Garrett et al., 1999; Raz et al., 2013). To this end, we denervated one of two paired mouse SLGs by cutting the chorda tympani (Figure 3A, the contralateral gland was used as an internal control). After 7 days, the neuronal genes Tubb3, Vip, and Vacht (Figure 3B, red bars), as well as GFRa2, were downregulated. + or TUBB3 + The transcript levels of the chorda tympani nerve (Figs. 3C and 12C) were significantly reduced, indicating successful denervation. Although no concomitant loss of cholinergic muscarinic receptor Chrml and Chrm3 transcripts was observed (Fig. 3B, red bars), it is possible that compensatory mechanisms may maintain Chrml and Chrm3 transcription in the absence of parasympathetic innervation. Although the SLG is mainly supplied by parasympathetic branches and has little sympathetic innervation in comparison (Emmelin et al., 1965), we observed a reduction in sympathetic innervation after chorda tympani section (Fig. 12A). Thus, although the sympathetic level was minor, we cannot exclude that part of the effect of denervation may be due to loss of sympathetic input.
[0106] Similar to the effects of radiation therapy on tissue architecture (Sullivan et al., 2005; Redman, 2008), adult acinar cells, as well as SOX2 + The precursors were more sensitive to loss of innervation than the ducts. Denervation led to a decrease in acinar cell size (as previously observed, Patterson et al., 1975, Figure 12B) and reduced AQP5 protein and transcript levels of the differentiated acinar cell marker Muc19 (Figures 3B and 3D). Interestingly, transcript and protein levels of MIST1 were unchanged after denervation (Figures 3B, 3E and 3F), suggesting that while functional markers of acinar cells are disrupted in the absence of innervation, acinar cell identity is not adversely affected. Surprisingly, SOX2 + Cells lose expression of Sox2 (Sox2 eGFP In mice, Sox2 protein and transcript levels were significantly reduced (Figures 3B, 3C, and 3F, and 12C), indicating that maintenance of SOX2 requires innervation. + To determine whether the cells retained the ability to repopulate tissue after denervation, we expressed cells expressing the endogenous Sox2 promoter (Sox2 CreERT2 ;Rosa26 mTmG ) driven Cre was activated 3 days after denervation and genetic lineage tracing was performed following the denervation until day 14. As shown in Figures 3G and 3H, SOX2 + Replacement of acinar cells by progenitors was significantly reduced (-50%) 14 days after transection. Similarly, in SLGs where recombination was induced before nerve transection (tamoxifen 1 day before transection), SOX2 + Replacement of acinar cells by precursors was significantly depleted (-50%) after 14 days (Figures 12E and 12F). The reduced replacement of acinar cells may be due to reduced cell proliferation rather than cell death, as we measured a reduction in Ccndl, but not in a marker of cell death [activated caspase-3 (CASP3) in Figure 12G]. +) cells, or Bax, Pmaipl (NOXA) and Bbc3 (PUMA) in Fig. 12H) were not observed or remained unchanged. The absence of cell death also suggests that cells previously positive for SOX2 continue to exist, but that cholinergic innervation is essential to maintain SOX2 expression.
[0107] To confirm that denervation preferentially affects the acinar lineage in the SLG, we also analyzed other epithelial cell lineages. + Ducts were similar to innervated controls, as were transcript levels of the duct genes Krt7, Krt8, and Krt19 (Figures 3B, 3D, and 3F). Furthermore, KRT5, a precursor that gives rise to SMG / SLG, is maintained by parasympathetic nerves (Knox et al., 2010). + Cells (Knox et al., 2010; Lombaert et al., 2013) were not affected by denervation (Figures 3F and 12; for transcriptional Krt5 expression, see Figure 3B). Based on these findings, SOX2 and SOX2 + We conclude that parasympathetic innervation is required for homeostasis of adult SLG tissue by preferentially maintaining and replacing functional acini through cellular regulation.
[0108] To determine whether re-supplying the salivary gland with nerves could rescue acini and SOX2, mouse salivary glands were examined 30 days after denervation. Plasticity of the peripheral nervous system results in the re-expression of TUBB3 at 30 days after transection. +Over time, mouse salivary glands become reinnervated, as indicated by the reappearance of nerves (Figure 9A) and re-expression of the neuronal genes Tubb3, Vip, and Vacht (Figure 3B, blue bars, Yawo, 1987). Surprisingly, we found elevated expression of these neuronal genes at 30 days (Figure 3B), suggesting hyperinnervation in response to the original injury. Notably, upon reinnervation, levels of Sox2 and Aqp5 transcripts and SOX2 protein, as well as SOX2 + and AQP5 + The number of cells, as well as acinar cell size, returned to control levels or above (Figures 3B and 9A-9C).
[0109] SLG's SOX2 + To ensure that cells can respond directly to acetylcholine produced by parasympathetic nerves, SOX2 + The expression of acetylcholine / muscarinic receptors by the cells and their ability to respond to muscarinic agonists in vivo were analyzed. + The cells expressed both CHRM1 and CHRM3 (95% and 99%, respectively; Figures 4A and 4B), and short-term treatment of wild-type mice with the muscarinic agonist pilocarpine (delivered IP and sacrificed at 18 hours) induced proliferation and SOX2 + The proportion of cells with SOX2 + Ki67 + cells, Figures 4C and 4D). However, SOX2 + The percentage of cells did not change significantly by 18 hours after injection (Figure 4D), indicating that muscarinic activation does not induce ectopic expression of SOX2. Thus, these data support the notion that parasympathetic activation via acetylcholine muscarinic signaling induces SOX2. + Supporting the hypothesis that it maintains progenitors and acini and promotes acinar cell replenishment.
[0110] Mouse salivary glands regenerate after radiation-induced injury via SOX2 Mouse salivary glands (mainly SMG) have been used extensively to investigate the effects of ionizing radiation (IR) on gland function and structure, where typical analyses are limited to degenerative responses. In a C57BL / 6 background, it has been reported to undergo acinar cell loss and reduced salivary flow after a single dose of 10 Gy (Zeilstra et al., 2000; Coppes et al., 2001, 2002). However, the regenerative capacity of the tissue and whether it remains innervated after IR is unknown. To test the effect of radiation on salivary gland regeneration via SOX2, we investigated the innervation, SOX2 expression, in mouse SLG after a single dose of gamma radiation to the head and neck. + We analyzed the role of IR in the regulation of IR in salivary glands, and in the recruitment of acinar cells via SOX2. Similar to previous studies in salivary glands (Avila et al., 2009), we found that a 10 Gy dose induced DNA damage and cell cycle arrest on the first day after IR, as well as reduced cell proliferation in SLGs, as shown by a substantial increase in the pro-apoptotic gene Bax and the cell cycle inhibitor Cdknla (p21) (Figure S13A) and a decrease in the transcript levels of the cell proliferation marker Mki67 (Figure S13A). Next, we investigated the role of TUBB3 in the regulation of IR in salivary glands, as well as in the regulation of acinar cell recruitment via SOX2. + We measured changes in innervation and neuronal function in the IR SLG by immunolabeling nerves and performing semi-quantitative PCR (qPCR) for Tubb3 and the parasympathetic neurotransmitter Vip. As shown in Figures 5A and 5B, TUBB3 in the IR SLG was significantly increased in the IR SLG compared with the control group. + Neurons were unchanged 1 and 3 days after radiation compared to non-IR controls. However, transcript levels of Tubb3 and Vip were significantly reduced 1 and 3 days after IR, suggesting that neuronal function is reduced at an early stage (Figure 13B). Similarly, transcripts of Sox2, Misti, and Aqp5 were reduced immediately after IR but returned to control levels by 7 days after IR (Figure 13B). SOX2 + The number of CCND1 cells was significantly reduced 1 day after IR (Figure 5C), whereas the number of CCND1 cells was significantly reduced 1 day after IR (Figure 5C). + SOX2 +The number of cells was significantly increased on days 3 and 7 after IR (Figure 5C). To determine whether SOX2-mediated cell replacement was affected after IR-induced injury, we analyzed Sox2 cells 14 days after IR. CreERT2 ;Rosa26 mTmG We analyzed the extent of SOX2-mediated recruitment in IR mice. Surprisingly, in IR SLGs as in non-IR controls, acinar cells express SOX2 + cells (GFP + cells) and SOX2 + GFP + Both SOX2- and SOX2-negative progeny were found to be produced (Figure 5D, white arrowheads indicate SOX2-negative progeny), which indicates that SOX2 + Instead, SOX2 + These results suggest the presence of transit-amplifying cells derived from IR cells (i.e., lineage traced). Furthermore, SOX2 expression in the IR SLG was not observed in the IR SLG. + The number of cells was similar to controls by day 14 (Figure 5D). Thus, despite the initial loss of neural signaling, SOX2, and acinar cell markers, the acinar compartment retained SOX2 expression after radiation-induced injury. + It can be replenished by cells.
[0111] We next tested whether SLGs could regenerate after IR injury in the absence of Sox2. As shown in Figure 5E, Sox2 CreERT2 ;Sox2 fl / fl Mice were unable to repopulate tissue with functional AQP5+ acini. Indeed, in the absence of Sox2, AQP5 was significantly reduced compared to wild-type mice 14 days after IR. + Loss of acinar cells and disruption of tissue architecture was observed (Figure 5E), further confirming that Sox2 is essential for SLG regeneration after radiation-induced injury.
[0112] SOX2+ cells can replenish irradiated salivary glands in response to cholinergic mimetics As our data suggest that cholinergic cues recruit the acinar lineage in SLG, we used an ex vivo lineage tracing model to investigate the upregulation of SOX2 in response to muscarinic activation in healthy and irradiated SLG. + We determined whether the cells could replenish the acini. As shown in Figure 6A and 6B, GFP-GFP cells were expressed in healthy SLG tissue cultured for 48 h with the acetylcholine mimetic carbachol (CCh). + There was an increase in clones. GFP + This increase in clones was due to the increased cell proliferation (Ki67 + In our IR model, Sox2 CreERT2 ;Rosa26 mTmG Recombination was induced in mice (Figure 6A). This time point was chosen because a lag time of 12–24 h was previously reported for tamoxifen-induced recombination of Cre lines in mice (Nakamura et al., 2006). Therefore, a single SOX2 + Cells are labeled by 24 hours after injection (see FIG. 6B, 0 hour panel). SLGs were harvested within 1 hour of radiation exposure and cultured ex vivo with or without CCh for 48 hours. As shown in FIG. 6B and quantified in FIG. 6C, GFP + Clones were more abundant in IR SLGs compared to non-IR controls and expressed IR-activated SOX2 + These results suggested that the cells repopulate the tissue. This could be attributed to cholinergic signaling from remaining nerves, as IR explants cultured with the muscarinic receptor antagonist 4-DAMP showed acinar cell recruitment similar to non-IR cultured salivary glands (Figures 6B and 6C). Importantly, treatment of IR explants with CCh significantly reduced the expression of GFP compared to IR alone. + Based on these data, SOX2 + We conclude that cells are able to repopulate IR SLGs in response to muscarinic activation.
[0113] Acetylcholine / muscarinic signaling maintains SOX2 and the acinar lineage in human SGs In humans, IR irreversibly reduces parasympathetic (and sympathetic) innervation in SGs (Knox et al., 2013, Fig. 14A, GFRA2), as well as markers of acinar lineage (AQP3, MIST1, AMY1), but not ductal lineage (EGFR, KRT19), compared to non-IR controls (Fig. 7A, IR was delivered approximately 2 years prior to surgery, n=7, IR and 11, non-IR). Lineage markers were confirmed in human tissues by immunofluorescence (SMGs were used due to availability) (Fig. 14B). Furthermore, transcript levels of SOX2, GFRA2, CHRM1, and CHRM3, but not tyrosine hydroxylase (TH, a sympathetic marker), were also significantly downregulated or trending toward downregulation after IR (Figs. 7A and 14A), indicating exhaustion of parasympathetic function, as well as the ability of cells to respond to acetylcholine. Thus, the loss of regenerative capacity of human salivary glands after IR is due to the downregulation of SOX2 +Due to reduced parasympathetic innervation of progenitor cells, we hypothesized that acetylcholine / muscarinic signaling is sufficient to maintain SOX2 expression and promote the acinar lineage. To test this hypothesis, we established a novel human explant-mouse nerve coculture system. In this model, non-irradiated human SMGs are dissected into <1 mm pieces and placed side-by-side with embryonic day 13 mouse submandibular parasympathetic ganglia (containing mesenchyme) or mesenchyme only (control, no nerve). The tissues are then cocultured for 7 days on filters floating on top of serum-free medium. Nerves migrated in and around the tissue (Figure 7B) and actively maintained tissue architecture as indicated by higher levels of CDH1 (E-cadherin, gene, and protein expression) in explants cocultured with nerves compared to mesenchyme alone (Figure 7C and 7D). We analyzed explants for the neuroattractants neurturin (NRTN) and nerve growth factor (NGF) in an attempt to ascertain which factors induced this neural migration (Knox et al., 2013). However, we found no increased expression in the presence of ganglia compared to mesenchyme alone (Figure 7D), suggesting that other neuroattractants were being synthesized, that the epithelium was producing these neuroattractants whether or not nerves were present (i.e., the mesenchyme was sufficiently supported to maintain epithelial homeostasis), or that this phenomenon occurred early in culture (i.e., when nerves were just beginning to surround the epithelium) and that any differences had resolved by this later time point (day 7). Strikingly, glandular explants cultured with nerves also showed increased transcript levels of SOX2 (~1.8- to 2-fold) as well as acinar markers MIST1 and CD44, and the muscarinic receptor CHRM3 (also expressed by acinar cells; Giraldo et al., 1988), compared with mesenchyme-only controls, whereas transcript levels of ductal genes KRT19, KIT, and EGFR were consistently lower (Figure 7D, data normalized to mesenchyme only, n = 2 independent individuals). Furthermore, Ki67 +Epithelial cell proliferation, characterized by the presence of endothelial cells, was increased in the presence of nerves (Figures 7C and 14C). Collectively, these data suggest that parasympathetic nerves can maintain SOX2 expression and acinar and ductal markers in human salivary glands.
[0114] Acetylcholine / muscarinic signaling regulates acini and SOX2 in human salivary glands +To address whether muscarinic stimulation is sufficient to maintain the cells, non-irradiated human SMG or PG (both express SOX2) tissue explants were subjected to muscarinic stimulation in an ex vivo system. Cultures of patient-derived human tissue from four separate individuals (n=4) with CCh significantly increased expression of SOX2, the muscarinic receptors CHRM1 and CHRM3 [both expressed by adult acinar cells (Giraldo et al., 1988; Mei et al., 1990)], as well as AQP3, AQP5 (Gresz et al., 2001), and MIST1 within 4 hours of muscarinic stimulation (Figure 7E, n=4, individual data sets shown in Figure 14D). Although surgical denervation does not adversely affect Misti expression (Figure 3B and 3E), muscarinic stimulation is sufficient to increase MIST1 in human cultures, suggesting that acetylcholine / muscarinic signaling may function as a positive regulator of the secretory program, although it is not required for acinar cell identity. The variability in responses among the four patient-derived samples is likely due to biological diversity among human patients, differences in the type of gland supplied (SMG and PG used), as well as the age of the patients (donor ages ranged from 30 to 78 years). However, in all cases, in the presence of CCh, we observed an increase in SOX2 and several acinar markers. We also measured an increase in KRT19 gene expression with CCh, whereas other exclusive ductal markers EGFR, KRT7, and KRT8 remained unchanged, suggesting that ductal cells are generally unresponsive to muscarinic agonists (Figure 7E). Given the increase in nerve ductal genes in human salivary glands in coculture, it is possible that other factors are produced by nerves that induce ductal changes (compare Figure 7D and 7E). Thus, neuronal acetylcholine / muscarinic signaling is sufficient to promote the acinar lineage and maintain SOX2 expression in adult human salivary glands.
[0115] Consideration Our study identifies SOX2 as a precursor in adult salivary glands essential for acini replenishment with the unexpected ability to repopulate the tissue after radiation-induced injury. +We further show that cholinergic nerves play a key role in controlling acinar cell replacement via SOX2 during homeostasis, and that this neuronal effect can be reproduced by adding a cholinergic mimetic to irradiated tissue. Thus, in contrast to the current dogma that mouse salivary glands do not regenerate after radiation-induced damage (Zeilstra et al., 2000; Coppes et al., 2001, 2002), these data show that, at least in mice, salivary glands have extensive regenerative capacity after radiation-induced damage. Furthermore, as we can see that the acinar lineage (and SOX2) in human tissues also responds to cholinergic mimetics, SOX2 is a key player in the regulation of acinar cell replacement via SOX2. + Targeting cells and preserving cholinergic nerves may help restore functional salivary acini after radiation therapy damage.
[0116] SOX2 has essential roles in organismal development and regulates homeostasis in epithelial tissues such as the stomach, trachea, and intestine (Arnold et al., 2011). SOX2 expression under both homeostatic and injury conditions was also shown to be impaired, as was the impairment of homeostatic capacity of adult tracheal cells following Sox2 ablation (Que et al., 2009). + AQP5 after ablation of Sox2 in acinar precursors + Interestingly, although atrophy occurred, we did not observe increased cell death in the absence of Sox2, but there was a substantial decrease in cycling acinar cells, suggesting that upon ablation, these cells leave the cell cycle and undergo differentiation to produce dormant AQP5-deficient acinar cells. +The striking loss of acini upon cell removal further confirms that these are the only precursors of the acinar lineage in SLG and is consistent with a recent report demonstrating that pancreatic acinar cells contain a subset of precursors, albeit not equipotent (Wollny et al., 2016). Our results contrast with a recent report by Aure and colleagues (Aure et al., 2015) showing that salivary acinar cells are replenished through self-renewal of mature cells, similar to pancreatic beta cells (Dor et al., 2004), without going through precursor differentiation. The conclusion that tissue repopulation is due to self-renewal of salivary acinar cells is supported by the SOX2 + MUC19 - The study was based on the use of the inducible Misti promoter, which is expressed by all acinar cells, including IL-1, IL-2, and IL-3. Thus, subsets of cells tracked upon recombination likely include progenitors, although no analysis was performed to determine whether these subsets possessed a stem cell signature.
[0117] As in all epithelial organs, peripheral nerves are required to maintain structural homeostasis in rodent and human salivary glands (Schneyer & Hall, 1967; Mandour et al., 1977; Wang et al., 1991; Fu & Gordon, 1995; Lujan et al., 1998; Kang et al., 2010; Batt & Bain, 2013). During organogenesis, parasympathetic nerves maintain a progenitor population that can contribute to the tissue after radiation injury via acetylcholine / muscarinic signaling (Knox et al., 2013). Previous denervation studies in salivary glands showed that organ and acinar cell size are reduced (Schneyer & Hall, 1967; Mandour et al., 1977; Kang et al., 2010), but it was not known whether innervation is required for acinar cell replacement. Here, we show that nerves directly regulate SOX2 to promote replacement of acinar cells from lineage-restricted precursors. This result is consistent with the well-known role of SOX2 in regulating self-renewal and cell fate in many other organs (Arnold et al., 2011). However, to date, only cell-intrinsic signaling pathways, including those mediated by the WNT, FGF, and EGFR families, have been shown to regulate SOX2 (Hashimoto et al., 2012; Dogan et al., 2014; Rothenberg et al., 2015; Lee et al., 2016). This extrinsic nerve-based model has a clear advantage over cell-intrinsic signals in that, unlike their target organs, neurons themselves are highly resistant to radiation damage (Tofilon & Fike, 2000; Wong & Van der Kogel, 2004). Whether this mechanism also regulates the maintenance of other SOX2-expressing epithelial organs, such as taste buds ( Suzuki, 2008 ), prostate and seminal vesicles ( Wanigasekara et al., 2004 ), stomach ( Tatsuta et al., 1985 ; Zhao et al., 2014 ), and cornea ( Ueno et al., 2012 ), remains to be tested.However, these results suggest that cholinergic nerves may function in the regeneration of these tissues.
[0118] Previous studies have utilized mouse salivary glands as a model for radiation-induced degeneration (Zeilstra et al., 2000; Coppes et al., 2001, 2002). These investigations were based on the assumption that regeneration is impaired after moderate to high doses of radiation, a hypothesis supported by the reduction in salivary flow measured in animals receiving radiation (Redman, 2008). However, no in vivo analysis of cell replacement after radiation has been performed to date. Our data show that mouse acinar cells are highly regenerative, at least for the first 30 days after radiation exposure, and are able to repopulate acini similar to uninjured controls. However, it is clear that this regenerative capacity cannot be maintained in the long term, as degeneration / senescence of mouse salivary glands occurs 3–6 months after radiation (Urek et al., 2005; Marmary et al., 2016). Thus, SOX2 + It is likely that the regenerative capacity of the cells will eventually fail, and further analysis is required to determine the cause. We also want to know whether human salivary glands can regenerate days / months after therapeutic radiation and whether SOX2 in combination with parasympathetic nerve activity can be used to stimulate regeneration. + Whether this regenerative capacity will not function in the long term due to the absence of cells remains to be determined. Indeed, time course analysis of changes in salivary glands from patients is necessary to understand how these organs are affected in the short and long term. However, our results suggest that targeting these stem cells and their innervation to control and maintain tissue regeneration in response to radiation injury may provide a means to maintain / repair tissue in the long term.
[0119] Many recent studies have aimed to address glandular regeneration after radiation injury in mouse models, either by isolating putative stem cell populations for reimplantation (Nanduri et al., 2013, 2014) or by sparing intraglandular regions thought to harbor stem cells (van Luijk et al., 2015). However, the identity of these endogenous stem cells and whether they contribute to the acinar cell compartment was unclear. Furthermore, the effects of such manipulations on salivary gland innervation have not been reported. Based on our study, we hypothesize that unintended increased innervation due to tissue perturbation may mediate the upregulation of SOX2, which regenerates acini and restores salivary function. + This may lead to the maintenance and expansion of progenitor cells. Xiao et al. (2014) reported the restoration of mouse saliva function and structure after radiation-induced damage by adding the neuroattractant glial-derived nerve factor (GDNF) (Knox et al., 2013). However, a recent study demonstrated that GDNF itself does not directly protect SG stem cells from radiation-induced damage (Peng et al., 2017), suggesting that such results may be the result of an improvement in the supportive niche.
[0120] Collectively, our studies highlight the extensive regenerative capacity of the salivary gland, which occurs through the expansion and differentiation of progenitor cell populations, even in the face of genotoxic shock. Based on these data, we hypothesize that SOX2 in the tissue + We propose that by directly targeting the cells, or by isolating and expanding these cells for transplantation and activation, it may be possible to regenerate the secretory portion of the salivary gland and restore quality of life to patients. + Maintenance of parasympathetic nerves would also be required to maintain populations, as previously proposed (Knox et al., 2013). Such a strategy may be applicable to the repair of multiple organ systems, as given organs such as the intestine, glandular stomach, trachea, and taste buds express SOX2, are strongly innervated by the autonomic nervous system, and are damaged by therapeutic radiation to eliminate cancer.
[0121] material and method Mouse strains All procedures were approved by the UCSF Institutional Animal Care and Use Committee (IACUC) and conformed to the NIH Guide for the Care and Use of Laboratory Animals. Mouse alleles used in this study were provided by The Jackson Laboratory and were Sox2 eGFP (Arnold et al., 2011), Sox2 CreERT2 (Smith et al., 2009), Sox2 fl / fl (Taranova et al., 2006), Rosa26 mTmG (Muzumdar et al., 2007), Rosa26 DTA (Wu et al., 2006), and Kit CreERT2 (Klein et al., 2013).
[0122] Animal testing Adult female mice (6–8 weeks old) were used in all experiments unless otherwise stated. Mice were housed at the AAALAC-accredited University of California San Francisco Parnassus campus Laboratory Animal Resource Center (LARC). Mice were housed in individually ventilated cages (IVCs) with fresh water, regular cleaning, and environmental enrichment, in groups of up to 5 mice per cage, whenever possible. Appropriate sample sizes were calculated using power calculations. For transgenic studies, sample sizes were limited by the length of time required to breed enough animals of the required genotype and sex. Wild-type animals were randomized into experimental groups using Microsoft Excel software. Transgenic animals were assigned to groups based on genotype. All animals were given unique ID numbers and were therefore blinded to the investigators during analysis.
[0123] Sox2 or SOX2 + Genetic ablation of cells Conditional ablation of Sox2 CreERT2 ;Sox2 fl / fl :R26 mTmG Mice were administered 2.5 mg / 20 g tamoxifen daily for 4 consecutive days and every 3 days before being euthanized on day 18. + Removal of cells was performed by deleting Sox2 cells prior to euthanasia on day 7. CreERT2 ;Rosa26 DTA :R26 mTmG This was done by injecting mice with 2.5mg / 20g of tamoxifen daily for four consecutive days. mTmG Mice provide a valuable tool for lineage tracing in combination with cell ablation / recombination (Muzumdar et al., 2007). Briefly, the model consists of a dual fluorescent Cre reporter that expresses membrane-targeted tandem dimer Tomato (mT) before Cre-mediated excision and membrane-targeted green fluorescent protein (mG) after excision (Figure 10D). Thus, in these mice, cells that have undergone recombination and therefore lack Sox2 or express DTA express GFP. Endogenous GFP was imaged in experiments using frozen sections, while a GFP antibody was used on paraffin-embedded tissues (chicken anti-GFP, 1:500, Aves Labs, GFP-1020).
[0124] SOX2 + Cell lineage tracing Sox2 CreERT2 ;Rosa26 mTmG Mice were injected with 2.5 mg of tamoxifen and euthanized 24 hours, 14 days, or 30 days later.
[0125] Lineage tracing of KIT+ cells Kit CreERT2 ;Rosa26 mTmG Mice were injected with 2.5 mg of tamoxifen daily for four consecutive days and euthanized after 14 days or 6 months.
[0126] In vivo denervation experiments C57BL / 6 or Sox2 eGFP Mice were anesthetized with inhalation of a 2% isoflurane / O2 mixture, administered with analgesics (carprofen and buprenorphine; Patterson Veterinary and Buprenex; 0.1 and 100 mg / kg (IP) respectively) 30 min prior to surgery. The surgical site was shaved and prepared for incision by alternating irrigation with iodine and alcohol followed by local anesthetic (lidocaine, Hospira Inc., 8 mg / kg). An incision was made in front of the ear, and the chorda tympani was positioned as previously described (Klimaschewski et al., 1996) and completely transected using spring scissors. The skin was sutured using nonabsorbable silk sutures (Ethicon) and the wound was further covered with surgical adhesive (Vetbond). The contralateral nerve was left intact as a control. After 7 or 30 days, mice were euthanized.
[0127] Pilocarpine experiment Adult male C57BL / 6 mice (6-8 weeks old) were treated with pilocarpine (Sigma-Aldrich, P0472; 0.68 mg / ml in 0.9% sterile saline). Mice were anesthetized using isoflurane and intraperitoneally injected with pilocarpine at a dose of 4.5 mg / kg body weight (200 μI) or with 0.9% saline as a vehicle control. Mice were euthanized 18 h later and glands were processed for immunofluorescence analysis.
[0128] Gamma ray experiment C57BL / 6 mice were anesthetized with 1.25% 2,2,2-tribromoethanol (Alfa Aesar) in 0.9% saline (Vedco Inc.). 137 By placing it in a Cs irradiator (JL Shepherd & Associates), 137 Mice were irradiated using a 1C source. Two lead blocks spaced 1.5 cm apart were used to shield the mouse's body and the very front of the mouth (nose), leaving only the neck and part of the head exposed. A 1.5 cm opening was placed at position 3 (137 The 3D scanner was centered 20 cm from the Cs source and 15.5 cm from the width of the irradiator cavity. To irradiate the salivary glands, mice were exposed to two doses of 5 Gy at a dose rate of 167 Rad / min for 2.59 min (one on each side of the head, bilaterally and sequentially, but performed on the same day) for a total dose of 10 Gy. This dose was calculated by isodose plot mapping (dose distribution) provided by the manufacturer, and EBT films (Brady et al., 2009) were used to identify the 100% exposed area for mouse placement. Control mice were anesthetized according to the experimental mice, but did not receive any radiation treatment. All mice were allowed to fully recover and fed a soft diet ad libitum (ClearH20) before returning to normal housing. Mice were euthanized after 1 h or after 1, 3, 7, 14, or 30 days.
[0129] Organ culture experiments Ex vivo lineage tracing in adult salivary glands Sox2 CreERT2 Salivary gland of origin; Rosa26 mTmG Mice (24 h prior to recombination induction) were mechanically dissected into sub-1 mm pieces, placed in complete medium with or without 200 nM CCh (Sigma-Aldrich) or 10 μM 4-DAMP (Tocris), cultured for 48 h, and then fixed for immunofluorescence. In some cases, mice were irradiated with three doses of 5 Gy before glands were taken for culture as described above.
[0130] Isolation and culture of human salivary gland tissue Adult human salivary glands were obtained from discarded, de-identified tissue with the consent of patients (28–78 years, males and females) undergoing cervical resection. All subjects gave informed consent, and experiments were performed in accordance with the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Patients had not received radiation therapy (non-IR) or had received fractionated radiation therapy (IR) less than 2 years prior to surgery. Tissues were immediately placed in 4% PFA, RNAlater (Qiagen) or DMEM (Thermo Fisher) for live cell explant culture. For ex vivo culture, non-IR tissues were dissected into pieces of <1 mm and cultured in serum-free DMEM / F12 containing holo-transferrin and ascorbic acid. For explant assays, tissues (SMG and PG) were incubated with 50–200 nM CCh (200 nM CCh is indicated in the results) for 4 h before dissolving RNA. For salivary gland explant-parasympathetic submandibular ganglion (SMG) cocultures, tissues were dissected into pieces smaller than 1 mm and cultured on floating filters on serum-free medium. E13 mouse parasympathetic submandibular ganglia were isolated as previously described (Knox et al., 2010). One parasympathetic submandibular ganglion per explant was placed next to a human salivary gland, cultured for 7 days, and fixed for immunofluorescence analysis or lysed for RNA.
[0131] Tissue processing After fixation, salivary glands (human and mouse) were processed for OCT or paraffin embedding. For the generation of frozen sections, tissues were incubated in increasing concentrations of sucrose (25–75%) and embedded in OCT. 12 μm sections were cut using a cryostat (Leica) and stored at -20 °C. Prior to embedding in paraffin wax (Sigma-Aldrich), tissues for paraffin were dehydrated by incubation in increasing concentrations of ethanol followed by incubation with Histo-Clear (National Diagnostics). 12 μm sections were cut using a microtome (Leica) and stored at room temperature.
[0132] Immunofluorescence analysis Whole-prep salivary gland and tissue section immunofluorescence analysis have been described previously (Knox et al., 2010). Briefly, tissues were fixed in either ice-cold acetone / methanol (1:1) for 1 min or 4% PFA for 20–30 min, followed by permeabilization with 0.1–0.3% Triton®X. Tissues were blocked overnight at 4°C with 10% donkey serum (Jackson Laboratories, ME), 1% BSA (Sigma-Aldrich), and MOM IgG blocking reagent (Vector Laboratories, CA) in 0.01% PBS-Tween® 20.Salivary glands were incubated overnight at 4°C with primary antibodies: goat anti-SOX2 (1:200, Neuromics, GT15098), goat anti-SOX10 (1:500, Santa Cruz Biotechnology, sc-17342), mouse anti-TUBB3 (clone TUJ1 at 1:400, R&D Systems, MAB1195), goat anti-GFRa2 (1:100, R&D Systems, AF429), rabbit anti-tyrosine hydroxylase (1:100, Millipore, AB152), rat anti-E-cadherin (1:300, Life Technologies, 13-1900), rabbit anti-EGFR (1:200, Abeam, ab52894), rabbit anti-KRT5 (1:1,000, Covance, PRB-160P), rat anti-KRT8 (1:200, DSHB, troma). I), mouse anti-KRT7 (1:50, Covance, MMS-148S), rat anti-CD44 (1:200, BioLegend, 103001), mouse anti-Ki67 (1:50, BD Biosciences, 550609), rabbit anti-CCND1 (1:200, Abeam, ab16663), rabbit anti-caspase-3 (1:100, Invitrogen, 34-1700), rabbit anti-AQP3 (1:400, Lifespan Biosciences) Antibodies were detected using Cy2-, Cy3-, or Cy5-conjugated secondary Fab fragment antibodies (Jackson Laboratories), and nuclei were stained using Hoechst33342 (1:1,000, Sigma-Aldrich). Fluorescence was analyzed using a LeicaSp5 confocal microscope and NIH ImageJ software.
[0133] Morphometric analysis and cell counts For immunofluorescence analysis (e.g., Figure 2D), cells stained positive for the markers were counted using ImageJ. Acinar cell size was measured using ImageJ. All data were obtained using 3–5 fields / group, and each experiment was repeated three times. For neuronal density analysis, immunofluorescence for the neuronal marker TUBB3 was analyzed and the raw integrated density (shown as arbitrary units, AU) was calculated using ImageJ.
[0134] Quantitative PCR analysis RNA was isolated from all tissues using the RNAqueous Micro Kit (Ambion). Total RNA samples were DNase treated (Ambion) prior to cDNA synthesis using Superscript reagent (Invitrogen, CA). SYBR green qPCR was performed using 5 ng (mouse) or 4–10 ng (human) cDNA and primers designed using Primer3 and Beacon Designer software or listed in PrimerBank (pga.mgh.harvard.edu / primerbank / ). Primer sequences are listed in Tables 1 and 2. Melting curves and primer efficiencies were determined as previously described (Hoffman et al., 2002). Gene expression was normalized to the housekeeping genes S18 and S29 (Rps18 and Rsp29), or GAPDH in mouse, and GAPDH in human, and the corresponding experimental controls. Reactions were performed in triplicate, and experiments were performed two to three times.
[0135] Flow cytometry Adult mouse sublingual salivary glands (CD1) were dissected and washed in PBS containing gentamicin (Sigma-Aldrich). Cell isolation and flow cytometry were performed as previously described (Muench et al., 2002; Pringle et al., 2011). Briefly, tissue in HBSS + 1% BSA (Sigma-Aldrich) was finely minced with a scalpel blade and single cell suspensions were created by incubating for 15-45 min at 37 °C in an HBSS solution containing 50 mM CaCh (Sigma-Aldrich), 40 mg / ml hyaluronidase (Sigma-Aldrich) and 23 mg / ml collagenase type II (Sigma-Aldrich). The enzymatic reaction was quenched by the addition of BSA, and the solution was filtered through a 70 μm strainer (BD Falcon) and centrifuged at 400 g for 8 min. The resulting cell pellet was washed with sterile HBSS + 1% BSA, centrifuged, and resuspended in blocking buffer (5% serum and 0.01% NaN3, BioLegend). Cell surface staining was achieved by incubating the cell suspension with antibodies against CD326 (EpCAM, Miltenyi, 130-098-113), rabbit anti-CHRM1 (Research and Diagnostics, AS-3701S), rabbit anti-CHRM3 (Research and Diagnostics, AS-3741S), and rabbit anti-AQP5 (Millipore, AB3559). Intracellular staining was then achieved after fixation and permeabilization using an intracellular staining kit (eBioscience, 00-5523-00), and antibodies against SOX2 (BD Pharmingen, 562195) and Ki67 (BioLegend, 652405). Flow cytometry was performed on an LSRII (BD) with appropriate single stain controls and data were collected using a FACSDiva (BD) and analyzed using FlowJo. 100,000 events were collected for each sample unless otherwise stated.
[0136] Statistical Tests Normal distribution was assessed using the D'Agostino-Pearson omnibus test. Data were analyzed for statistical significance using Student's t-test (unpaired, two groups) or one-way ANOVA (multiple groups), and post-hoc tests were performed using Dunnett's or Tukey's tests (GraphPad Prism or SPSS). For multiple testing, a false discovery rate of 0.05 was used. All graphs show the mean + standard deviation (SD) or mean ± standard error (SEM) as indicated in the legend.
[0137] References Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C (2006) Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol 42:57-65
[0138] Arnold K,Sarkar A,Yram MA,Polo JM,Bronson R,Sengupta S,Seandel M,Geijsen N,Hochedlinger K(2011)Sox2(+)adult stem and progenitor cells are important for tissue regeneration and survival of mice.Cell Stem Cell
[0139] 9:317-329
[0140] Aure MH, Konieczny SF, Ovitt CE (2015) Salivary gland homeostasis is maintained through acinar cell self-duplication.Dev Cell 33:231-237
[0141] Avila JL,Grundmann O,Burd R,Limesand KH(2009)Radiation-induced salivary gland dysfunction results from p53-dependent apoptosis.Int J Radiat Oncol Biol Phys 73:523-529
[0142] Barker N(2014)Adult intestinal stem cells:critical drivers of epithelial homeostasis and regeneration.Nat Rev Mol Cell Biol 15:19-33
[0143] Batt JA,Bain JR(2013)Tibial nerve transection-a standardized model for denervation-induced skeletal muscle atrophy in mice.J Vis Exp 81:e50657
[0144] Brady SL,Toncheva G,Dewhirst MW,Yoshizumi TT(2009)Characterization of a 137Cs irradiator from a new perspective with modern dosimetric tools.Health Phys 97:195-205
[0145] Brown LR,Dreizen S,Handler S,Johnston DA(1975)Effect of radiation- induced xerostomia on human oral microflora.J Dent Res 54:740-750
[0146] Coppes RP,Zeilstra LJ,Kampinga HH,Konings AW(2001)Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists.Br J Cancer 85:1055-1063
[0147] Coppes RP,Vissink A,Konings AW(2002)Comparison of radiosensitivity of rat parotid and submandibular glands after different radiation schedules.Radiother Oncol 63:321-328
[0148] Dogan I,Kawabata S,Bergbower E,Gills JJ,Ekmekci A,Wilson W ill,Rudin
[0149] CM,Dennis PA(2014)SOX2 expression is an early event in a murine
[0150] model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.Lung Cancer 85:1-6
[0151] Dor Y,Brown J,Martinez OI,Melton DA(2004)Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation.Nature
[0152] 429:41-46
[0153] Dreizen S,Brown LR,Daly TE,Drane JB(1977)Prevention of xerostomia- related dental caries in irradiated cancer patients.J Dent Res 56:99-104
[0154] Dusek M,Simmons J,Buschang PH,al-Hashimi I(1996)Masticatory function in patients with xerostomia.Gerodontology 13:3-8
[0155] Emami B,Lyman J,Brown A,Coia L,Goitein M,Munzenrider JE,Shank B,Solin LJ,Wesson M(1991)Tolerance of normal tissue to therapeutic irradiation.Int J Radiat Oncol Biol Phys 21:109-122
[0156] Emmelin N,Holmberg J,Ohlin P(1965)Receptors for catechol amines in the submaxillary glands of rats.Br J Pharmacol Chemother 25:134-138
[0157] Emmerson E,May AJ,Nathan S,Cruz-Pacheco N,Lizama CO,Maliskova L,Zovein AC,Shen Y,Muench MO,Knox SM(2017)SOX2 regulates acinar cell development in the salivary gland.eLife 17:e26620
[0158] Erb W(1868)Zur Pathologie und pathologischen Autonomie peripherischer
[0159] Paralysen.Dtsch Arch klin Med 4:535
[0160] Fu SY,Gordon T(1995)Contributing factors to poor functional recovery after delayed nerve repair:prolonged denervation.J Neurosci 15:3886-3895
[0161] Garrett JR,Ekstrom J,Anderson LC(1999)Neural mechanisms of salivary gland secretion.Basel:Karger
[0162] Giraldo E,Martos F,Gomez A,Garcia A,Vigano MA,Ladinsky H,Sanchez de La Cuesta F(1988)Characterization of muscarinic receptor subtypes in human tissues.Life Sci 43:1507-1515
[0163] Gresz V,Kwon TH,Hurley PT,Varga G,Zelles T,Nielsen S,Case RM,Steward MC(2001)Identification and localization of aquaporin water channels in human salivary glands.Am J Physiol Gastrointest Liver Physiol 281:G247-G254
[0164] Grundmann O,Mitchell GC,Limesand KH(2009)Sensitivity of salivary glands to radiation:from animal models to therapies.J Dent Res 88:894-903
[0165] Hashimoto S,Chen H,Que J,Brockway BL,Drake JA,Snyder JC,Randell SH,Stripp BR(2012)beta-Catenin-SOX2 signaling regulates the fate of developing airway epithelium.J Cell Sci 125:932-942
[0166] Hoffman MP,Kidder BL,Steinberg ZL,Lakhani S,Ho S,Kleinman HK,Larsen M(2002)Gene expression profiles of mouse submandibular gland development:FGFR1 regulates branching morphogenesis in vitro through BMP-and FGF-dependent mechanisms.Development 129:5767-5778
[0167] Kang JH,Kim BK,Park BI,Kim HJ,Ko HM,Yang SY,Kim MS,Jung JY,Kim WJ,Oh WM et al(2010)Parasympathectomy induces morphological changes and alters gene-expression profiles in the rat submandibular gland.Arch Oral Biol 55:7-14
[0168] Klein S,Seidler B,Kettenberger A,Sibaev A,Rohn M,Feil R,Allescher HD,Vanderwinden JM,Hofmann F,Schemann M et al(2013)Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity.Nat Commun 4:1630
[0169] Klimaschewski L,Grohmann I,Heym C(1996)Target-dependent plasticity of galanin and vasoactive intestinal peptide in the rat superior cervical ganglion after nerve lesion and re-innervation.Neuroscience 72:265-272
[0170] Knox SM,Lombaert IM,Reed X,Vitale-Cross L,Gutkind JS,Hoffman MP(2010)Parasympathetic innervation maintains epithelial progenitor cells during salivary organogenesis.Science 329:1645-1647
[0171] Knox SM,Lombaert IM,Haddox CL,Abrams SR,Cotrim A,Wilson AJ,Hoffman MP(2013)Parasympathetic stimulation improves epithelial organ regeneration.Nat Commun 4:1494
[0172] Lee NY,Le GT(2008)New developments in radiation therapy for head and neck cancer:intensity-modulated radiation therapy and hypoxia targeting.Semin Oncol 35:236-250
[0173] Lee MJ,Kim EJ,Otsu K,Harada H,Jung HS(2016)Sox2 contributes to tooth development via Wnt signaling.Cell Tissue Res 365:77-84
[0174] Lombaert IM,Brunsting JF,Wierenga PK,Faber H,Stokman MA,Kok T,Visser WH,Kampinga HH,de Haan G,Coppes RP(2008)Rescue of salivary gland function after stem cell transplantation in irradiated glands.PLoS One 3:e2063
[0175] Lombaert IM,Abrams SR,Li L,Eswarakumar VP,Sethi AJ,Witt RL,Hoffman MP(2013)Combined KIT and FGFR2b signaling regulates epithelial progenitor expansion during organogenesis.Stem Cell Reports 1:604-619
[0176] van Luijk P,Pringle S,Deasy JO,Moiseenko VV,Faber H,Hovan A,Baanstra M,van der Laan HP,Kierkels RG,van der Schaaf A et al(2015)Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer.Sci Transl Med 7:305ra147
[0177] Lujan M,Paez A,Llanes L,Angulo J,Berenguer A(1998)Role of autonomic innervation in rat prostatic structure maintenance:a morphometric analysis.J Urol 160:1919-1923
[0178] Mandour MA,Helmi AM,El-Sheikh MM,El-Garem F,El-Ghazzawi E(1977)Effect of tympanic neurectomy on human parotid salivary gland.Histopathologic,Histochemical,and Clinical Study.Arch Otolaryngol 103:338-341
[0179] Marmary Y,Adar R,Gaska S,Wygoda A,Maly A,Cohen J,Eliashar R,Mizrachi L,Orfaig-Geva C,Baum BJ et al(2016)Radiation-induced loss of salivary gland function is driven by cellular senescence and prevented by IL6 modulation.Can Res 76:1170-1180
[0180] Mei L,Roeske WR,Izutsu KT,Yamamura HI(1990)Characterization of muscarinic acetylcholine receptors in human labial salivary glands.Eur J Pharmacol 176:367-370
[0181] Muench MO,Suskind DL,Barcena A(2002)Isolation,growth and identification of colony-forming cells with erythroid,myeloid,dendritic cell and NK-cell potential from human fetal liver.Biol Proced Online 4:10-23
[0182] Muzumdar MD,Tasic B,Miyamichi K,Li L,Luo L(2007)A global double- fluorescent Cre reporter mouse.Genesis 45:593-605
[0183] Nakamura E,Nguyen MT,Mackem S(2006)Kinetics of tamoxifen-regulated Cre activity in mice using a cartilage-specific CreER(T)to assay temporal activity windows along the proximodistal limb skeleton.Dev Dyn 235:2603-2612
[0184] Nanduri LS,Lombaert IM,van der Zwaag M,Faber H,Brunsting JF,van Os RP,Coppes RP(2013)Salisphere derived c-Kit cell transplantation restores tissue homeostasis in irradiated salivary gland.Radiother Oncol 108:458-463
[0185] Nanduri LS,Baanstra M,Faber H,Rocchi C,Zwart E,de Haan G,van Os R,Coppes RP(2014)Purification and ex vivo expansion of fully functional salivary gland stem cells.Stem Cell Reports 3:957-964
[0186] Nelson DA,Manhardt C,Kamath V,Sui Y,Santamaria-Pang A,Can A,Bello M,Corwin A,Dinn SR,Lazare M et al(2013)Quantitative single cell analysis of cell population dynamics during submandibular salivary gland development and differentiation.Biol Open 2:439-447
[0187] Ogawa M,Oshima M,Imamura A,Sekine Y,Ishida K,Yamashita K,Nakajima K,Hirayama M,Tachikawa T,Tsuji T(2013)Functional salivary gland regeneration by transplantation of a bioengineered organ germ.Nat Commun 4:2498
[0188] Owens DM,Watt FM(2003)Contribution of stem cells and differentiated cells to epidermal tumours.Nat Rev Cancer 3:444-451
[0189] Patterson J,Lloyd LC,Titchen DA(1975)Secretory and structural changes in the parotid salivary gland of sheep and lambs after parasympathetic denervation.Q J Exp Physiol Cogn Med Sci 60:223-232
[0190] Peng X,Varendi K,Maimets M,Andressoo JO,Coppes RP(2017)Role of glial-cell-derived neurotrophic factor in salivary gland stem cell response to irradiation.Radiother Oncol 124:448-454
[0191] Peterson SC,Eberl M,Vagnozzi AN,Belkadi A,Veniaminova NA,Verhaegen ME,Bichakjian CK,Ward NL,Dlugosz AA,Wong SY(2015)Basal cell carcinoma preferentially arises from stem cells within hair follicle and mechanosensory niche.
[0192] Pringle S,Nanduri LS,van der Zwaag M,van Os R,Coppes RP(2011)Isolation of mouse salivary gland stem cells.J Vis Exp 8:2484
[0193] Pringle S,Maimets M,van der Zwaag M,Stockman MA,van Gosliga D,Zwart E,Witjes MJ,de Haan G,van Os R,Coppes RP(2016)Human salivary gland stem cells functionally restore radiation damaged salivary glands.
[0194] Gue J,Luo X,Schwartz RJ,Hogan BL(2009)Multiple roles for Sox2 in the developing and adult mouse trachea.Development 136:1899-1907
[0195] Raz E,Saba L,Hagiwara M,Hygino de Cruz LC Jr,Som PM,Fatterpekar GM(2013)Parotid gland atrophy in patients with chronic trigeminal nerve denervation.AJNR Am J Neuroradiol 34:860-863
[0196] Redman RS(2008)On approaches to the functional restoration of salivary glands damaged by radiation therapy for head and neck cancer,with a review of related aspects of salivary gland morphology and development.Biotech Histochem 83:103-130
[0197] Rothenberg SM,Concannon K,Cullen S,Boulay G,Turke AB,Faber AC,Lockerman EL,Rivera MN,Engelman JA,Maheswaran S et al(2015)Inhibition of mutant EGFR in lung cancer cells triggers S0X2-F0X06-dependent survival pathways.eLife 4:e06132
[0198] Schneyer CA,Hall HD(1967)Effects of denervation on development of function and structure of immature rat parotid.Am J Physiol 212:871-876
[0199] Seidel K,Marangoni P,Tang C,Houshmand B,Du W,Maas RL,Murray S,Oldham MC,Klein OD(2017)Resolving stem and progenitor cells in the adult mouse incisor through gene co-expression analysis.eLife 5:e24712
[0200] Siegel RL,Miller KD,Jemal A(2015)Cancer statistics,2015.CA Cancer J Clin
[0201] 65:5-29
[0202] Smith AN,Miller LA,Radice G,Ashery-Padan R,Lang RA(2009)Stage-dependent modes of Pax6-Sox2 epistasis regulate lens development and eye morphogenesis.Development 136:2977-2985
[0203] Sullivan CA,Haddad RI,Tishler RB,Mahadevan A,Krane JF(2005)Chemoradiation-induced cell loss in human submandibular glands.Laryngoscope 115:958-964
[0204] Suzuki Y(2008)Expression of Sox2 in mouse taste buds and its relation to innervation.Cell Tissue Res 332:393-401
[0205] Taranova OV,Magness ST,Fagan BM,Wu Y,Surzenko N,Hutton SR,Pevny LH(2006)SOX2 is a dose-dependent regulator of retinal neural progenitor competence.Genes Dev 20:1187-1202
[0206] Tatsuta M,Yamamura H,Iishi H,Ichii M,Noguchi S,Baba M,Taniguchi H(1985)Promotion by vagotomy of gastric carcinogenesis induced by
[0207] N-methyl-N’-nitro-N-nitrosoguanidine in Wistar rats.Can Res 45:194-197
[0208] Tofilon PJ,Fike JR(2000)The radioresponse of the central nervous system:a dynamic process.Radiat Res 153:357-370
[0209] Ueno H,Ferrari G,Hattori T,Saban DR,Katikireddy KR,Chauhan SK,Dana R(2012)Dependence of corneal stem / progenitor cells on ocular surface innervation.Invest Ophthalmol Vis Sci 53:867-872
[0210] Urek MM,Bralic M,Tomac J,Borcic J,Uhac I,Glazar I,Antonie R,Ferreri S(2005)Early and late effects of X-irradiation on submandibular gland:a morphological study in mice.Arch Med Res 36:339-343
[0211] Von Vintschgau M,Honigschmied J(1877)Nervus Glossopharyngeus und Schmeckbecher.Arch Gesammte Physiol 14:443-448
[0212] Wallace H(1972)The components of regrowing nerves which support the regeneration of irradiated salamander limbs.J Embryol Exp Morphol 28:419-435
[0213] Wang JM,McKenna KE,McVary KT,Lee C(1991)Requirement of innervation for maintenance of structural and functional integrity in the rat prostate.Biol Reprod 44:1171-1176
[0214] Wanigasekara Y,Airaksinen MS,Heuckeroth RO,Milbrandt J,Keast JR(2004)Neurturin signalling via GFRalpha2 is essential for innervation of glandular but not muscle targets of sacral parasympathetic ganglion neurons.Mol Cell Neurosci 25:288-300
[0215] Wollny D,Zhao S,Everlien I,Lun X,Brunken J,Brune D,Ziebell F,Tabansky I,Weichert W,Marciniak-Czochra A et al(2016)Single-cell analysis uncovers clonal acinar cell heterogeneity in the adult pancreas.Dev Cell 39:289-301
[0216] Wong CS,Van der Kogel AJ(2004)Mechanisms of radiation injury to the central nervous system:implications for neuroprotection.Mol Interventions 4:273-284
[0217] Wu S,Wu Y,Capecchi MR(2006)Motoneurons and oligodendrocytes are sequentially generated from neural stem cells but do not appear to share common lineage-restricted progenitors in vivo.Development 133:581-590
[0218] Xiao N,Lin Y,Cao H,Sirjani D,Giaccia AJ,Koong AC,Kong CS,Diehn M,Le QT(2014)Neurotrophic factor GDNF promotes survival of salivary stem cells.J Clin Invest 124:3364-3377
[0219] Xiao Y,Thoresen DT,Williams JS,Wang C,Perna J,Petrova R,Brownell I(2015)Neural Hedgehog signaling maintains stem cell renewal in the sensory touch dome epithelium.Proc Natl Acad Sci USA 112:7195-7200
[0220] Yawo H(1987)Changes in the dendritic geometry of mouse superior cervical ganglion cells following postganglionic axotomy.J Neurosci 7:3703-3711
[0221] Zeilstra LJ,Vissink A,Konings AW,Coppes RP(2000)Radiation induced cell loss in rat submandibular gland and its relation to gland function.Int J Radiat Biol 76:419-429
[0222] Zhao CM,Hayakawa Y,Kodama Y,Muthupalani S,Westphalen CB,Andersen GT,Flatberg A,Johannessen H,Friedman RA,Renz BW et al(2014)Denervation suppresses gastric tumorigenesis.Sci Transl Med 6:250ra115
[0223] Example 2 Therapeutic activation of endogenous salivary gland stem cell populations by local delivery of muscarinic agonists in injectable alginate hydrogels An alternative regenerative approach to restore salivary function is stem cell therapy, where autologous stem / progenitor cells are transplanted into injured organs or surviving stem cells within tissues are reactivated. However, the progenitor cells that give rise to salivary secreting acinar cells, the major cell type damaged by radiation and autoimmune disease, were previously unknown. We recently identified SOX2 as a marker of epithelial progenitor cells in mouse salivary glands (Emmerson et al., 2018). SOX2+ acinar cells are found in all major human salivary glands (submandibular (SMG)) and comprise 20% of the acinar compartment in mouse sublingual glands (SLG). We found that maintenance of SOX2+ cells and tissue homeostasis depends on parasympathetic production of acetylcholine, which activates muscarinic receptors to promote cell proliferation. We further showed that the muscarinic mimetics carbachol and pilocarpine can promote SOX2+ cell proliferation after in vivo and / or ex vivo delivery, and that muscarinic agonism promotes salivary gland regeneration after radiation injury. Collectively, these studies strongly suggest that reactivation of pre-existing stem cells is a feasible strategy for organ regeneration.
[0224] Here, we test the ability of localized and sustained cevimeline delivery to promote stem cell-mediated repopulation of salivary glands. Specifically, we devised a combination product involving encapsulation of a muscarinic agonist in a biodegradable calcium-crosslinked alginate hydrogel for localized, targeted, and sustained delivery to the salivary glands. Using a combination of in vitro and in vivo studies, we defined the chemistry of the alginate-based hydrogel that allows for linear distribution within the tissue and sustained delivery of the muscarinic receptor agonist cevimeline. In vivo studies in mice demonstrate that the encapsulated drug is effective in promoting stem cell proliferation within the salivary glands of both control and irradiated animals in a manner consistent with sustained delivery. Thus, we provide a novel therapeutic agent for salivary gland regeneration and restoration of salivary flow.
[0225] result Cevimeline promotes cell proliferation when delivered via local injection Given previous findings that systemic administration of muscarinic mimetics promotes salivary gland proliferation, we next determined whether local intraglandular injection was also able to promote a mitogenic response. To determine whether cevimeline could act locally in the salivary gland to induce acinar cell proliferation, we injected 10 mg / kg body weight (20 μI) of cevimeline directly into the sublingual gland and measured proliferation 18 hours later. As shown in Figure 15, acinar cell proliferation was significantly increased (Figure 15), indicating that cevimeline can act directly in the salivary gland to promote cell mitosis.
[0226] Engineered biodegradable calcium cross-linked alginate hydrogels Based on the efficacy of localized cevimeline delivery to promote cell proliferation, we next set out to develop an injectable drug delivery platform for the localized and sustained release of cevimeline to promote acinar regeneration. To this end, we chose to utilize a calcium-crosslinked alginate-based biomaterial for the delivery of cevimeline. Alginate is a naturally occurring anionic polymer extracted from brown algae. Alginate is an attractive candidate for the treatment of acinar regeneration due to its biocompatibility, minimal toxicity, relatively low cost, and low Ca 2+Calcium-crosslinked alginate is an FDA-approved hydrogel used in many biomedical applications due to its ability to be crosslinked under cytocompatible conditions using divalent cations such as Calcium-1, Calcium-2, and Calcium-3. (Lee et al. (2012) Prog. Polym. Sci. 37(1):106-126) Calcium-crosslinked alginate is structurally similar to the extracellular matrix of living tissues, is highly hydrophilic, and maintains a physiologically moist microenvironment. Importantly, alginate can be resuspended at concentrations that allow injection through clinically relevant syringe-needles systems, during which shear forces disrupt the electrostatic crosslinks and linearly deform the material, but the gelation spontaneously reforms in vivo.
[0227] Alginate is essentially non-degradable in mammals due to the lack of the polymer chain cleavage enzyme arginase. However, ionically cross-linked alginate gels are released into the surrounding medium and dissolved by exchange reactions of the divalent ions cross-linking the gel with monovalent cations such as sodium ions. Alginate degradation rates can be further controlled by partial oxidation of the polymer chains. Important for FDA approval as a therapeutic rather than an implantable agent, alginate hydrogels must degrade by 30 days after injection. However, to achieve sustained delivery of cevimeline, alginate should be present for a 7+ day period. To meet this degradation profile, the alginate chains were partially oxidized at either 2% or 5%. In vitro degradation studies show that the two hydrogels have significantly different degradation profiles, with slow degradation being achieved with the 2% oxidized alginate (OA) hydrogel. (Figure 16A) The 2% OA hydrogel maintains more than 50% of its gel mass for nearly 5 days in vitro, whereas the 5% OA hydrogel loses this mass in 1 day. After in vitro degradation studies over 7 days of culture, approximately 30% of the 2% OA hydrogels versus 14% of the 5% OA hydrogels remains.
[0228] Based on this longer physical retention period, we chose to use 2% OA hydrogel. We next tested how the weight percentage (wt%) of 2% OA hydrogel affected physical degradation. Although 10 wt% of 2% OA hydrogel degraded significantly slower than 2 wt% or 5 wt%, this concentration could not be easily injected through the small bore needles (>23 gauge) required for in vivo delivery to the salivary glands (Figure 16B).
[0229] The physical degradation of the 2% OA hydrogel at 5 wt% was then tested under more physiologically relevant conditions by injecting 100 μl of hydrogel into a subcutaneous pocket on the dorsal aspect of wild-type mice. This amount of hydrogel forms a small disk within minutes, which can then be removed and weighed for analysis. In contrast to the in vitro system, we found that in vivo, almost no mass loss was found 7 days after injection (Figure 16C), indicating that this hydrogel is suitable for in vivo delivery of cevimeline.
[0230] Another factor important to commercial viability is the storage stability of solubilized alginate. To slow degradation, solubilized oxidized alginate presumed that the material would need to be stored at 4 °C or <-20 °C, but the specific impact of these storage conditions on material stability is unknown. Therefore, the change in compressive modulus of calcium cross-linked alginate after storage of solubilized oxidized alginate at 4 °C or -20 °C for 30 days was examined. When 5 wt. % 2% OA hydrogels were stored under refrigerated conditions (4 °C), cross-linking efficacy was significantly affected by a decrease in compressive modulus over 20 days, suggesting degradation of the oxidized alginate (Figure 16C). However, maintaining the alginate under frozen conditions (-20 °C) stabilized the initial material properties 30 days after synthesis.
[0231] Localized and sustained release of cevimeline from alginate hydrogels Pharmaceutical applications of alginate have traditionally involved utilizing hydrogels for the controlled release of various low molecular weight drugs. Crosslinked alginate forms a nanoporous material with the theoretical pore size of our material predicted at approximately 5 nm, considering the starting molecular weight is 197 kDa. The controlled release of the drug is regulated primarily through electrostatic interactions between the positively charged cevimeline (pKA=9.5) and the negatively charged alginate hydrogel. In vitro cevimeline release studies demonstrate that the release of the drug can be sustained over a period of two days. (Figure 17) Despite altering the physical degradation characteristics (Figures 16A-16B), neither the amount of oxidation (OA%) nor the weight percent (wt%) of the alginate hydrogel significantly affected the drug release kinetics, with over 85 ± 5% of the cevimeline released in vitro by two days. (Figures 17A-17B) To test whether changing the starting concentration of drug affected release, we loaded each disk with either 3,000 ng, 60,000 ng, or 12,000 ng of cevimeline and tested the release in vitro. The release rate remained relatively consistent (Figure 17C), resulting in a predictable increase in the amount of drug delivered over the course of two days (Figure 17D).
[0232] Cevimeline promotes glandular cell proliferation when encapsulated in alginate Next, given this successful drug delivery platform, the efficacy, toxicity, and degradation of alginate + cevimeline were tested in vivo. Due to the small size of mouse salivary glands, to avoid complications caused by tissue damage, we chose not to inject the hydrogel directly into the gland, but into an area directly adjacent to the gland so that it could be visualized by X-ray (Figure 18A, Omnipaque encapsulated as a radiopaque contrast agent). Alginate or saline with or without 10 mg / kg cevimeline was injected adjacent to the salivary gland, and the salivary glands were analyzed 18 hours (Figure 18C, n=3-4 per group) or 3 days (Figure 18, n=3-6 per group) after injection. As shown in Figure 18, we measured a significant increase in the number of proliferating Ki67+ and EdU+ acinar cells at day 3 in response to 10 mg / kg alginate + cevimeline compared to alginate alone (Figure 18C, 18D), consistent with the drug having prolonged activity when combined with alginate. We saw a similar increase in proliferating Ki67+ acinar cells at day 3 in response to the higher 25 mg / kg alginate + cevimeline, suggesting that increasing the dose does not significantly improve efficacy (Figure 18). We also tested whether alginate itself is mitogenic by comparing cell proliferation within the glands of mice treated with alginate alone to mice that only received an intraperitoneal (IP) injection of saline. We found that alginate alone was sufficient to promote epithelial cell proliferation and did so over a period of 3 to 7 days (Figure 23), indicating that the combination has a beneficial impact.
[0233] To determine whether alginate or alginate + cevimeline treatment showed toxic effects in mice, mouse body weight was measured and inflammatory cells in the salivary glands were characterized. We found that increasing doses of alginate + cevimeline did not cause weight loss by 3 days after injection (Figure 24). Furthermore, no toxic effects such as diarrhea were observed compared to saline-injected controls. Immunohistological analysis of CD3+ T cells also showed no increase compared to tissues derived from untreated or aged (positive control) mice (Figures 19A, 19B). Analysis of CD68+ macrophages, the major innate immune cells and first responders to injury, suggested a slight increase in these cells in response to alginate or alginate + cevimeline treatment when directly compared to untreated controls (Figures 19C, 19D). Further analysis of macrophage populations showed that pro-repair CD206+ macrophages were significantly increased in alginate-treated tissues when compared to saline-treated controls (Figure 19E), suggesting that alginate may have a beneficial effect on the salivary glands by activating anti-inflammatory macrophages.
[0234] Effect of cevimeline-alginate on salivary glands after radiation-induced damage We next tested whether cevimeline or alginate + cevimeline could promote cell proliferation in salivary glands after gamma radiation-induced injury. 7-8 week-old C57BL6 mice were irradiated with a single 10 Gy dose in the neck and 14 days later, either saline or 10 mg / kg cevimeline was injected systemically or intraperitoneally and the number of proliferating acinar cells was analyzed 18 hours later (see schematic in Figure 20A). This level of radiation reduces citrate-induced salivary flow by 30% (Figure 20B). We found that both systemic and local administration of cevimeline increased acinar cell proliferation in irradiated mice (Figures 20C-20E), indicating that cevimeline is effective in damaged salivary glands.
[0235] Finally, we tested whether cevimeline encapsulated in alginate promoted cell proliferation and salivary flow rate. 14 days after radiation, mice were injected with alginate or alginate + cevimeline and sacrificed at 3 days for analysis of proliferation (Figure 21A schematic). Alginate + cevimeline increased the proliferation rate above the levels of alginate alone (Figure 21B, 21C). We further determined whether treatment with alginate or alginate + cevimeline aided salivary flow rate. Strikingly, both alginate and alginate + cevimeline were able to increase citrate-induced salivary flow rate for 7 days (Figure 21D), suggesting that alginate itself benefits the irradiated organ.
[0236] Consideration Oral administration of muscarinic agonists is prescribed to stimulate the temporary production of saliva in patients suffering from xerostomia, but is accompanied by common side effects such as excessive sweating, facial flushing, urinary urgency, gastrointestinal discomfort, and headache. Here, we show that local release of the muscarinic agonist cevimeline from an injectable calcium-crosslinked alginate hydrogel can promote acinar cell recruitment and improve salivary gland function after radiation-induced injury without eliciting an immune response. This represents the first in vivo evidence that acinar precursors in irradiated tissue can be stimulated to proliferate and that muscarinic receptor activation is sufficient to achieve this outcome. We also demonstrate that calcium-crosslinked alginate alone stimulates a pro-regenerative response in addition to sustaining the release of the small molecule cevimeline over a 3-day period. Taken together, these findings provide a potential new combination therapy for reversing salivary gland dysfunction after radiation-induced injury that may be suitable for a variety of dry mouths.
[0237] Our therapy builds on evidence from over the past 100 years that peripheral nerves are essential for salivary gland function, homeostasis, and regeneration. Parasympathetic denervation results in atrophy of secretory acini that can be reversed through tissue reinnervation (Emmerson et al., 2018). Because parasympathetic innervation is significantly reduced in salivary glands from patients who have undergone therapeutic radiation for head and neck cancer (Emmerson et al., 2018), we questioned whether resupplying atrophied tissue with nerve-derived factors could restore tissue structure and function. The in vivo experiments presented here follow our previous ex vivo studies demonstrating increased neuronal survival and function following radiation exposure in fetal salivary glands, or that treating irradiated adult tissue with muscarinic agonists is sufficient to promote acinar cell replenishment by a progenitor cell-mediated mechanism (Knox 2013, Emmerson 2018). Furthermore, current data also suggest that improved salivary flow following chronic oral administration of muscarinic agonists in mice and humans with irradiated salivary glands (Barbe 2017; Taniguchi 2019) may be due to acinar cell recruitment rather than reduced cell death. However, whether human acinar cells can proliferate in response to muscarinic stimulation remains to be determined.
[0238] Many strategies have been explored for the regeneration of irradiated salivary glands. Our therapeutic application aims to mimic the endogenous regulation of the tissue by the parasympathetic nervous system through the provision of an acetylcholine homologue. This approach is similar to recent gene therapy studies that aim to resupply the organ with functional nerves through the expression of the neurotrophic growth factor neurturin. Other strategies have utilized growth factors known to promote branching morphogenesis during embryonic development: intraglandular administration of fibroblast growth factor 7 (FGF7, Lombaert et al., 2009; Xiao et al., 2014), or systemic delivery of insulin-like growth factor 1 (Grundmann (2010) BMC Cancer 10:417), or gene delivery of sonic hedgehog (Shh) via ductal cannulation (Hai et al. (2016) Hum. Gene Ther. 27(5):390-399), to improve salivary function and tissue preservation in irradiated salivary glands. However, the uptake of these agents in the clinic has been hampered by their potential to accelerate cancer growth. Although chronic oral administration of pilocarpine has not been shown to be tumorigenic, further studies are needed to determine whether topical administration of cevimeline affects cancer initiation, progression, or metastasis.
[0239] Previous studies have shown calcium cross-linked alginate hydrogels to promote wound healing in various organ systems including bone, cartilage, and skin (Wang et al. (2015) Int. J. Clin. Exp. Pathol. 8(6):6636-6645). However, whether this function is directly mediated through cell proliferation, survival, and / or migration remains largely unknown. Our data show that calcium alginate has the ability to promote tissue regeneration in irradiated salivary glands by inducing cell proliferation. A possible mechanism to achieve this is through the elevation of extracellular calcium. Calcium that is not cross-linked to the polysaccharide backbone may be released directly from the alginate into the extracellular space (Doyle et al. (1996) J. Biomed. Mater. Res. 32(4):561-568) or may be released during the degradation of the material. This Ca is then 2+ The depot activates the calcium-sensing receptor to increase intracellular Ca 2+ Calcium-sensing receptors are present in many cell types, including acinar cells, and therefore alginate-derived Ca 2+ It is proposed that ions may function as pro-mitotic agents through stimulation of these receptors.
[0240] Ca from calcium alginate gel 2+ It has been recently reported that the release of cevimeline can also be pro-inflammatory (Chan et al. (2013) Acta Biomater. 9(12):9281-9291). When calcium alginate was given subcutaneously in mice, it significantly upregulated IL-ip in the surrounding tissue and enhanced the inflammatory effects of LPS. However, our results show that calcium alginate with or without cevimeline is highly biocompatible and causes little or no inflammation when injected into the area surrounding the salivary glands.
[0241] One of the key properties required for hydrogels is the ability to provide sustained drug release. Drug molecules, from small chemicals to macromolecular proteins, can be released from alginate gels in a controlled manner, depending on the type of crosslinker and the crosslinking method. In fact, multiple chemicals have been applied to control the kinetics of drug release, such as crosslinking.
[0242] material and method Synthesis of OA Oxidized sodium alginate (OA) was prepared by reacting sodium alginate (Protanal LF20 / 40, alginate MW = 197,000 Da, FMC biopolymer #S18407) with sodium periodate (Sigma, catalog #311448) using a modification of a previously described method. Briefly, sodium alginate (10 g) was dissolved in ultrapure deionized water (diH2O, 900 ml) overnight. Sodium periodate (0.22 g) was dissolved in 100 ml of diH2O and added to the alginate solution while stirring at room temperature (RT) in the dark. After 24 h of reaction, the reaction was stopped by the addition of ethylene glycol (52 μI, Sigma). OA was purified by dialysis against diH2O (MWCO = 3500 Da, Spectrum Laboratories Inc.) for 3 days, treated with activated charcoal (5 g / l, 50-200 mesh, Fisher, 05-690B) for 30 min, filtered (0.22 pm filter), and lyophilized.
[0243] To analyze the oxidation efficiency of OA, OA was dissolved in deuterium oxide (5 wt / vol %) and placed in an NMR tube. 13 C-NMR spectra were recorded on a Bruker ADVANCE III 400 MHz NMR spectrometer (Bruker) using 3-(trimethylsilyl)propionic acid-d4 sodium salt (0.05 w / v%) as an internal standard. The actual oxidation was estimated based on the ratio of the integrals of carbon to carbonyl carbon of the newly formed aldehyde by oxidation of alginate. 13 This was determined from the H-NMR spectrum (Figure 25).
[0244] Synthesis of calcium cross-linked OA hydrogels OA is kept at -20 °C in lyophilized form until ready to form hydrogels. Hydrogels are formed by dissolving OA in Dulbecco's Modified Eagle Medium (DMEM, Gibco #11885084) at the desired weight / volume (wt%) at room temperature for a minimum of 30 min under constant stirring. OA is crosslinked by mixing with supersaturated calcium sulfate (CaS04, 84 mg / mL) solution at a concentration of 20 μL of CaS04 per wt% per mL of alginate (e.g., 40, 100, and 200 pL of CaS04 mixed with 1 mL of 2%, 5%, and 10 wt% alginate, respectively). OA solution and CaS04 slurry were loaded separately into two 1 mL syringes. After connecting the two syringes together with a female-female Luer lock coupler (Value Plastics), the two syringes were mixed (approximately 30 times).
[0245] Physical degradation of oxidized alginate hydrogels In vitro physical degradation of OA hydrogels was tested by creating 1 mmx4 mm disks with either 2% or 5% oxidation at 2 wt%, 5 wt%, or 10 wt% weight / volume. Disks were formed by using a 25 gauge needle to inject OA hydrogels between two glass plates separated by a 1.0 mm spacer. Gels polymerized at room temperature after 30-45 min and a biopsy punch was used to create a 4 mm diameter disk. Gels were transferred to 0.4 pm transwells (Millicell, #MCHT12H48) in 12-well plates containing 3.2 ml of DMEM and plates were continuously shaken (100 RPM) at 37 °C. Hydrogels were collected at To (initial control), 4 h, 1 day, 3 days, 5 days, and 7 days (D). Three hydrogels were pooled with an average of 3-5 separate replicates (samples) at each time point. Samples were frozen at -80°C and then lyophilized (VirTis Wizard 2.0). Dry weight was measured on an analytical balance (Mettler Toledo AT201).
[0246] In vivo degradation assays were performed using a mouse subcutaneous assay. All experiments were approved by the UCSF Institutional Animal Care and Use Committee (IACUC). Animals were anesthetized using isoflurane (2.5% induction, 1.5% maintenance), the skin was washed with 70% ethanol, and then 100 μI of OA hydrogel gel was injected into individual subcutaneous pockets on the dorsal flank of the mice using a 25-gauge needle (maximum of 6 hydrogels / animal). Mice were socially housed and monitored for signs of pain and distress for 48 hours. Animals were allowed to survive for 18 hours, 3 days, 5 days, or 7 days. At the end of the day, gels were microdissected from the subcutaneous pockets, frozen at -80°C, lyophilized, and dry weights were recorded as done for in vitro degradation.
[0247] OA Stability 2% OA polymer was dissolved at 5 wt% as described above, drawn into 3 ml syringes, and stored at 4°C or -20°C. At 1, 4, 10, 20, or 30 days after dissolution, syringes (n=5 / time) were removed from storage, allowed to return to room temperature, and then crosslinked by mixing the OA solution with a supersaturated calcium sulfate slurry as described above. After mixing, the crosslinked OA was immediately placed between two glass plates separated by a 0.75 mm spacer and allowed to form a hydrogel for 30 minutes at room temperature. A 6 mm diameter biopsy punch was used to create calcium crosslinked OA hydrogel disks. To assess the stability of the OA solution, the elastic modulus of the calcium crosslinked OA hydrogels over time was measured. The elastic modulus of the hydrogels was determined by performing uniaxial, unconfined constant strain rate compression testing at room temperature using a constant crosshead speed of 1% per second on a mechanical testing machine (225 lbs actuator, TestResources) equipped with a 5 N load cell. Elastic moduli were calculated from the first non-zero linear slope of the stress versus strain plot, limited to the first 5% of strain.
[0248] Mass spectrometry for the determination of cevimeline A Shimadzu Prominence LC-20ADXR system connected to a 4500QTrap mass spectrometer equipped with an electrospray ionization (ESI) source was operated for LC-MS / MS analysis. Chromatographic separation was achieved using a Phenomenex KineteX® C18 (50×3 mm, 2.6 pm) column coupled with a Phenomenex SecurityGuard C18 guard column (3 mm×2.0 mm). The column temperature was controlled at 30° C. Mobile phase A was 0.1% trifluoroacetic acid in water and mobile phase B was acetonitrile (ACN). The injection volume was 10 pL and the flow rate was 0.5 mL / min. The gradient conditions were as follows: (time / min, mobile phase B%): (0, 15), (1, 15), (2.5, 22.8), (2.6, 98), (5, 98), (5.1, 15), and (8, 15). Source parameters included curtain gas at 45 psi, ion spray voltage at 4000 V, ion source temperature at 550, and medium collision gas. A summary of the MS / MS parameter settings in positive ion ESI mode is presented in Table 1.
[0249] Standard working solutions of cevimeline were prepared over the range of 10.0-10000.0 ng / mL in methanol. Working solutions were spiked into 100 µl of DMEM to generate standards or QC samples. Final concentrations of calibration standards were 0.5, 1.0, 2.5, 5.0, 10.0, 25.0, 50.0, and 100.0, 250.0, and 500 ng / mL in DMEM. QC samples were 0.9, 4, 30.0, and 400.0 ng / mL.
[0250] For the sample preparation step, 10 μL of IS working solution (1000 ng / mL) was added for every 100 μL of DMEM. A 96-well protein precipitation filter plate Sigma-Aldrich (St. Louis, MO) and 300 pI of MeOFLACN (15:85) were used for protein precipitation. After filtration, 200 pI of NH4OH 5% was added to 200 pI of sample and 10 pI was injected into the LCMS system. The bioanalytical method was validated according to the current guidelines of the US FDA, including selectivity, linearity, intra-day and inter-day precision and accuracy, recovery and stability ("Guidance for Industry, Bioanalytical Method Validation," 2018 fda.gov / media / 70858 / download). [Table 1]
[0251] Cevimeline release from alginate hydrogels In vitro cevimeline (CV) release from OA hydrogels was tested by creating 1mmx4mm disks with either 2 or 5% oxidation at 2, 5, or 10% w / v. Alginate+cevimeline (Abeam, ab141317) hydrogels were created by resuspending the drug at the desired concentration in DMEM before mixing with lyophilized OA, with subsequent crosslinking proceeding as described above to encapsulate the drug with the OA hydrogel. Three 4mm alginate+cevimeline hydrogels were placed into 0.4μm transwells of a 12-well plate containing 3.2ml DMEM incubated at 37°C with slow continuous agitation (100RPM). Sample medium (3ml DMEM) was collected and replenished at 4 hours, 1 day, 2 days, 3 days, 4 days, 5 days, and 7 days (D). The three hydrogels were pooled with an average of 3-5 separate replicates (samples) at each time point. Sample media were stored at -20°C until mass spectrometry was performed. Graphs are only shown up to day 4 as all cevimeline had been released by that time. To (initial control) gels were dissolved in DMEM to establish a baseline of cevimeline encapsulated in the hydrogels.
[0252] Animal testing Adult female mice (6–8 weeks old) from the C57 / BL6 inbred strain (Harlan Laboratories) were used for all experiments unless otherwise stated. All procedures were approved by the UCSF Institutional Animal Care and Use Committee (IACUC) and conformed to the NIH Guide for the Care and Use of Laboratory Animals.
[0253] In vivo cevimeline delivery Cevimeline was prepared as previously described and delivered by intraperitoneal (IP) injection using a 0.5 ml Monoject™ Tuberculin syringe with a 28G1 / 2 needle (Covidien) for free cevimeline, or by subcutaneous injection using a 1 ml TB syringe with a 25G×5 / 8 needle (Becton Dickinson) for cevimeline mixed with alginate.
[0254] For intestinal injection of cevimeline, mice were administered analgesics (carprofen and buprenorphine; Patterson Veterinary and Buprenex; 0.1 mg / kg and 100 mg / kg (IP) respectively) 30 min before surgery and anesthetized by inhalation of a 2% isoflurane / O2 mixture. The surgical site was shaved and washed alternately with iodine and alcohol, followed by local anesthetic (lidocaine, Hospira Inc., 8 mg / kg) and prepared for incision. An incision was made in the throat along the craniocaudal axis using spring scissors. Cevimeline was then injected into the lobes of the submandibular and sublingual salivary glands using 2 27Gx1 / 2 needles (Becton Dickinson) attached to a slip-tip tuberculin syringe (Becton Dickinson). The skin was sutured using non-absorbable silk sutures (Ethicon). Mice were euthanized after 18 h, 3 days, or 7 days, and some animals were injected with 0.9% saline containing 0.25 mg / 25 g of 5-ethynyl-2′-deoxyuridine (EdU, Thermofisher Scientific) 2 h before sacrifice.
[0255] Gamma ray treatment Animals were anesthetized with 100 μl / 10 gbw of 2.5% Avertin (2,2,2-tribromoethanol (Alfa Aesar), tert-amyl alcohol (2-methyl-2-butanol) (Spectrum)) in 0.9% saline (Vedco Inc.). Mice were placed in a Shepherd Mark I irradiator (JL Shepherd & Associates). The body was shielded from radiation using a lead block and the head and neck region was exposed to two 5 Gy doses (10 Gy total) to irradiate the salivary glands (SG). Control mice were anesthetized but did not receive any radiation treatment. All mice were allowed to recover fully and fed a soft diet (ClearHaO) ad libitum before returning to normal housing.
[0256] Saliva collection Mice were anesthetized using 2% inhaled isoflurane or avertin (for radiation studies). 5 mg of sodium citrate (Spectrum Chemical) in 12.5 pi sterile water was dropped into the mouth of the mouse. After 2 min, a piece of filter paper was inserted into the animal's mouth and left under anesthesia for 5 min. The amount of secreted saliva was determined by measuring the weight of the filter paper before and after collection using a precision scale (Denver Instrument SI-64, di=0.1 mg).
[0257] Tissue processing After euthanasia, SGs were collected, snap frozen, and embedded in OCT. 10 pm frozen sections were cut using a cryostat (Leica) and used for immunofluorescence studies.
[0258] Immunofluorescence study Tissue sections were processed for immunofluorescence analysis as follows: Briefly, fresh frozen tissues were fixed with 4% PFA for 10 min at room temperature, then permeabilized with 0.5% Triton®-X100 for 10 min at room temperature. Tissues were blocked with 10% donkey serum (Jackson Laboratories, ME), 5% BSA (Sigma Aldrich), and MOM IgG blocking reagent (Vector Laboratories, CA) in 0.01% PBS-Tween®-20 for 2 h at room temperature. SG sections were incubated overnight at 4°C with primary antibodies: rabbit anti-AQP5 (1:200, Millipore, AB3559), goat anti-SOX2 (1:200, Neuromics, GT15098), rabbit anti-Ki67 (1:200, AbCam, ab16667), rat anti-Ki67 (1:200, DAKO, M7249), rabbit-CHRM3 (1:1000, Research Diagnostics, AS-3741S), rat anti-E-cadherin (1:400, Invitrogen, 13-1900). Antibodies were detected using Cy2-, Cy3- or Cy5-conjugated secondary Fab fragment antibodies (1:300, Jackson Laboratories), and nuclei were stained using Hoescht33342 (1:1000, AnaSpec Inc.). EdU staining was performed using Click-iT EdU Alexa-Fluor 488 or 647 kits (Invitrogen). Slides were mounted using Fluoromount-G (Southern Biotech) and fluorescence was analyzed using a Leica Sp5 confocal microscope. Image processing and quantification were performed using NIH ImageJ software.
[0259] statistics Statistical tests were performed using GraphPad Prism software v8. Data are presented as mean ± SD and were subjected to ordinary one-way ANOVA with two-tailed unpaired Student's t-test for two datasets or Tukey's multiple comparison test for three or more datasets. Significance was assessed using the indicated P-value cutoffs: *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. Specific dataset analyses are described in the figure legends. The present invention provides, for example, the following items. (Item 1) A composition comprising a muscarinic agonist encapsulated in a hydrogel formulated for local administration to the salivary glands for use in treating xerostomia. (Item 2) 2. The composition of claim 1, wherein the muscarinic agonist is selective for the M1 and / or M3 muscarinic receptor subtypes. (Item 3) 3. The composition of claim 2, wherein the muscarinic agonist is cevimeline. (Item 4) 2. The composition of claim 1, wherein the muscarinic agonist is pilocarpine. (Item 5) 5. The composition according to any one of items 1 to 4, wherein the hydrogel comprises an alginate. (Item 6) 6. The composition of claim 5, wherein the alginate is ionically crosslinked. (Item 7) 7. The composition of claim 6, wherein the alginate is ionically crosslinked with divalent calcium cations. (Item 8) 8. The composition according to any one of items 5 to 7, wherein the concentration of the alginate in the hydrogel is in the range of about 2 to about 10 weight percent (wt%). (Item 9) 8. The composition according to any one of items 5 to 7, wherein the alginate is at least partially oxidized. (Item 10) 9. The composition of claim 8, wherein about 2% to about 10% of the alginate is oxidized. (Item 11) 10. The composition of claim 9, wherein about 2% of the alginate is oxidized and the concentration of the alginate in the hydrogel is about 5% by weight. (Item 12) 12. The composition of any one of items 1-11, wherein the hydrogel maintains delivery of the muscarinic agonist for at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks after administration to a subject. (Item 13) 13. The composition according to any one of items 1 to 12, further comprising a pharma- ceutically acceptable excipient. (Item 14) 14. The composition according to any one of items 1 to 13, further comprising an imaging agent. (Item 15) 15. A method for treating a subject with xerostomia, comprising topically administering to the salivary glands of said subject a therapeutically effective amount of the composition according to any one of items 1 to 14. (Item 16) 16. The method of claim 15, wherein the composition is injected into or adjacent to the salivary gland. (Item 17) 17. The method of claim 15 or 16, further comprising performing medical imaging or palpation to identify the location of the salivary gland prior to injection. (Item 18) 20. The method of claim 17, wherein the medical imaging comprises performing an ultrasound. (Item 19) 19. The method of any one of items 15 to 18, wherein multiple therapeutically effective doses of the composition are administered to the subject. (Item 20) 20. The method according to any one of items 15 to 19, wherein the xerostomia is caused by damage to the salivary glands due to radiation or Sjogren's syndrome. (Item 21) 21. The method according to any one of items 15 to 20, wherein the subject is a pet or livestock. (Item 22) 22. The method according to any one of items 15 to 21, wherein the subject is a mammal. (Item 23) 23. The method of claim 22, wherein the mammal is a dog, cat, horse, cow, goat, sheep, or pig. (Item 24) 23. The method of claim 22, wherein the mammal is a human. (Item 25) 15. A kit comprising the composition according to any one of items 1 to 14 and instructions for treating xerostomia. (Item 26) 26. The kit of claim 25, further comprising a means for delivering the composition to a subject. (Item 27) 26. The kit of claim 25, further comprising a first syringe containing a composition comprising a muscarinic agonist encapsulated in an alginate hydrogel, a second syringe containing a solution comprising calcium chloride, and a Luer lock, wherein the second syringe can be connected to the first syringe via the Luer lock. (Item 28) 28. The kit of claim 27, wherein the first syringe containing the composition comprising the muscarinic agonist encapsulated in an alginate hydrogel is frozen. (Item 29) 29. The kit according to any one of items 25 to 28, wherein the muscarinic agonist is cevimeline or pilocarpine. (Item 30) 1. A method of promoting salivary gland regeneration in a subject in need thereof, comprising locally administering at least one of a cholinergic or muscarinic agonist to acinar progenitor cells and acinar cells of the salivary gland to promote proliferation of said acinar progenitor cells and said acinar cells, thereby increasing saliva production. (Item 31) The acinar progenitor cells are + The method according to item 30, wherein the cells are acinar progenitor cells. (Item 32) 32. The method of claim 30 or 31, wherein the muscarinic agonist is encapsulated in a hydrogel formulated for local administration to the salivary gland. (Item 33) 33. The method of claim 32, wherein the hydrogel comprises alginate. (Item 34) 34. The method of claim 33, wherein the alginate is ionically crosslinked. (Item 35) 35. The method of claim 34, wherein the alginate is ionically crosslinked with divalent calcium cations. (Item 36) 36. The method according to any one of items 33 to 35, wherein the concentration of the alginate in the hydrogel is in the range of 2 to 10 weight percent (wt%). (Item 37) 37. The method according to any one of items 33 to 36, wherein the alginate is at least partially oxidized. (Item 38) Item 38. The method of item 37, wherein about 2% to about 10% of the alginate is oxidized. (Item 39) 39. The method of claim 38, wherein about 2% of the alginate is oxidized and the concentration of the alginate in the hydrogel is about 5% by weight. (Item 40) 40. The method of any one of items 30 to 39, wherein the muscarinic agonist is selective for the M1 and / or M3 muscarinic receptor subtypes. (Item 41) 41. The method of claim 40, wherein the muscarinic agonist is cevimeline. (Item 42) 40. The method according to items 30 to 39, wherein the muscarinic agonist is pilocarpine. (Item 43) 43. The method of any one of items 32-42, wherein the hydrogel maintains delivery of the muscarinic agonist for at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks after administration to the subject. (Item 44) The acinar progenitor cells are + 44. The method according to any one of items 30 to 43, wherein the cells are EdlT acinar progenitor cells. (Item 45) 45. The method of any one of items 30 to 44, wherein said acinar cell proliferation in response to said muscarinic agonist results in increased saliva flow. (Item 46) 46. The method according to any one of items 30 to 45, wherein the salivary gland is the sublingual gland. (Item 47) 47. The method of any one of items 30 to 46, wherein the cholinergic agent comprises at least one of acetylcholine or an acetylcholine analogue. (Item 48) 48. The method of claim 47, wherein the acetylcholine analog comprises carbachol. (Item 49) The acinar progenitor cells are + 49. The method according to any one of items 30 to 48, wherein the cell is a cell. (Item 50) 50. The method according to any one of items 30 to 49, wherein the acinar progenitor cells are mucin (MUC)19- cells. (Item 51) SOX2 from the salivary glands of the subject+ 2. Isolating Acinar Progenitor Cells and SOX2 + 51. The method of any one of items 30 to 50, further comprising expanding acinar progenitor cells. (Item 52) 52. The method of claim 51, wherein the expanded cells are provided in an engineered tissue construct or biocompatible matrix that provides a controlled release of the at least one cholinergic or muscarinic agonist to the expanded cells, wherein the controlled release comprises at least one of delayed release, sustained release, gradient release, time release, patterned release, or spatial release. (Item 53) 53. The method of claim 52, wherein the expanded cells and the at least one cholinergic or muscarinic agonist are provided on and / or in a biodegradable natural polymer or macromer. (Item 54) 54. The method of claim 53, wherein the biodegradable natural polymer or macromer comprises a hydrogel. (Item 55) 55. The method of any one of items 30 to 54, wherein the subject has been treated with radiation effective to induce xerostomia.
Claims
1. 1. A composition comprising cevimeline or pilocarpine encapsulated in a hydrogel formulated for local intraglandular administration to the salivary glands for use in treating xerostomia, wherein the hydrogel comprises an alginate.
2. The composition of claim 1 , wherein the alginate is ionically crosslinked.
3. The composition of claim 2 , wherein the alginate is ionically crosslinked with divalent calcium cations.
4. The composition of claim 2 or 3, wherein the concentration of the alginate in the hydrogel ranges from about 2 to about 10 weight percent (wt %).
5. The composition of claim 2 or 3, wherein the alginate is at least partially oxidized.
6. The composition of claim 4, wherein about 2% to about 10% of the alginate is oxidized.
7. 6. The composition of claim 5, wherein about 2% of the alginate is oxidized and the concentration of the alginate in the hydrogel is about 5% by weight.
8. 8. The composition of any one of claims 1 to 7, wherein the hydrogel maintains delivery of the cevimeline or pilocarpine for at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks after administration to a subject.
9. The composition of any one of claims 1 to 8, further comprising a pharma- ceutically acceptable excipient.
10. The composition of any one of claims 1 to 9, further comprising an imaging agent.
11. 11. The composition of any one of claims 1 to 10 for use in a method of treating a subject with xerostomia, said method comprising topically administering a therapeutically effective amount of said composition to a salivary gland of said subject.
12. The composition of claim 11 , wherein the composition is injected into or adjacent to the salivary gland.
13. 13. The composition of claim 11 or 12, wherein the method further comprises performing medical imaging or palpation to identify the location of the salivary gland prior to injection.
14. The method of claim 13 , wherein the medical imaging comprises performing an ultrasound.
15. The composition of any one of claims 11 to 14, wherein multiple therapeutically effective doses of the composition are administered to the subject.
16. The composition of any one of claims 11 to 15, wherein the xerostomia is caused by damage to the salivary glands due to radiation or Sjogren's syndrome.
17. The composition according to any one of claims 11 to 16, wherein the subject is a pet or livestock.
18. The composition according to any one of claims 11 to 17, wherein the subject is a mammal.
19. 20. The composition of claim 18, wherein the mammal is a dog, cat, horse, cow, goat, sheep, or pig.
20. The composition of claim 18 , wherein the mammal is a human.
21. A kit for treating xerostomia comprising a composition according to any one of claims 1 to 10 and instructions for treating xerostomia.
22. 22. The kit of claim 21, further comprising a means for delivering the composition to a subject.
23. 22. The kit of claim 21, further comprising a first syringe containing a composition comprising cevimeline or pilocarpine encapsulated in an alginate hydrogel, a second syringe containing a solution comprising calcium chloride, and a Luer lock, wherein the second syringe can be connected to the first syringe via the Luer lock.
24. 24. The kit of claim 23, wherein the first syringe containing the composition comprising the cevimeline or pilocarpine encapsulated in an alginate hydrogel is frozen.
25. 1. A composition comprising cevimeline or pilocarpine encapsulated in a hydrogel formulated for local intraglandular administration to a salivary gland for use in a method of promoting salivary gland regeneration in a subject in need thereof, the method comprising locally administering the composition to acinar progenitor cells and acinar cells of a salivary gland to promote proliferation of the acinar progenitor cells and acinar cells, thereby increasing saliva production, the hydrogel comprising alginate.
26. The acinar progenitor cells are + The composition of claim 25 which is an acinar progenitor cell.
27. 27. The composition of claim 25 or 26, wherein the alginate is ionically crosslinked.
28. 28. The composition of claim 27, wherein the alginate is ionically crosslinked with divalent calcium cations.
29. The composition of any one of claims 25 to 28, wherein the concentration of the alginate in the hydrogel ranges from 2 to 10 weight percent (wt %).
30. The composition according to any one of claims 25 to 29, wherein the alginate is at least partially oxidized.
31. 31. The composition of claim 30, wherein about 2% to about 10% of the alginate is oxidized.
32. 32. The composition of claim 31, wherein about 2% of the alginate is oxidized and the concentration of the alginate in the hydrogel is about 5% by weight.
33. 33. The composition of any one of claims 25 to 32, wherein the hydrogel maintains delivery of the cevimeline or pilocarpine for at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks after administration to the subject.
34. The acinar progenitor cells are + Or EdU+ acinar progenitor cells.
35. A composition according to any one of claims 25 to 34, wherein said acinar cell proliferation in response to said cevimeline or pilocarpine results in increased salivary flow.
36. The composition of any one of claims 25 to 35, wherein the salivary gland is the sublingual gland.
37. The acinar progenitor cells are SOX2+ / AQP5+ / Ki67 + The composition of any one of claims 25 to 36, which is a cell.
38. The acinar progenitor cells are - The composition of any one of claims 25 to 37, which is a cell.
39. The method comprises administering to the subject a salivary gland extract of SOX2 + Isolating acinar progenitor cells and + The composition of any one of claims 25 to 38, further comprising expanding acinar progenitor cells.
40. The composition of claim 39, wherein the expanded cells are provided in an engineered tissue construct or biocompatible substrate that provides a controlled release of the cevimeline or pilocarpine to the expanded cells, the controlled release comprising at least one of delayed release, sustained release, gradient release, time release, patterned release, or spatial release.
41. 41. The composition of claim 40, wherein the expanded cells and the cevimeline or pilocarpine are provided on and / or within a biodegradable natural polymer or macromer.
42. The composition of claim 41 , wherein the biodegradable natural polymer or macromer comprises a hydrogel.
43. The composition of any one of claims 25 to 42, wherein the subject is being treated with radiation effective to induce xerostomia.
Citation Information
Patent Citations
Polymer containing polysaccharide such as alginate or modified alginate
JP2009120855A
Methods for treating tissue damage induced by radiation or chemotherapy
JP2011504924A
Salivation accelerator for percutaneous salivary gland administration
JP2016210701A
Saliva secretion promoting pharmaceutical composition for oral mucosa administration
JP2017066126A
Implantable modular hydrogel for salivary gland restoration
WO2013090924A1
